spot on biotechnology business 2015/16

BIO.NRWMerowingerplatz 1 40225 Düsseldorf, GermanyFon +49 211 385469-9200Fax +49 211 [email protected]

Ministry of Innovation, Science and Research of the German State of North Rhine-Westphalia 40221 Düsseldorf www.innovation.nrw.de

www.exzellenz.nrw.de With the “Excellence NRW” cluster strategy, North Rhine-Westphalia has set new standards for both business and innovation. The state government has made the systematic improvement of NRW’s strengths and talents an absolute priority – both in established industries and up-and-coming fields like biotechnology. It is our goal to create a favorable climate for innovation, as that is the best way to sustain the competitive edge and stimulate growth and employment in the companies that call the state home. To find out more about North Rhine-Westphalia’s cluster strategy and the 16 clusters currently in NRW’s roster, just visit www.exzellenz.nrw.de. w

ww

.bio

.nrw

.de

Company

Directory

Spot on Biotechnology Business 2015/2016

Online

Company

Database

www.bio.nrw.de

Online

Company

Database

www.bio.nrw.de

From Mind to Market: Biotechnology Company Directory 2015/2016

North Rhine-Westphalia

4

BIO.NRW

5

BIO.NRW

Editorial

capital in Germany, combined with a rather unfavorable and internationally barely com-petitive tax law situation. Thus, sources of private equity, venture capital, foundations and public funding that are still within reach for a biotech company are becoming more selective. At the same time, alliances with global companies of the pharmaceutical or chemical industry are becoming more important. One of Europe’s biggest cross-industry consortium that has success-fully started operation is the EIT Health with an overall budget of up to EUR 2 bn. and with over 140 partner organizations from 16 European countries (www.eithealth.eu). BIO.NRW signed as founding associate member to EIT Health.

A vast amout of direct answers to the questions raised at the beginning are worked out by the 105 biotech compa-nies from North Rhine-Westphalia (NRW) presented in this 2015/2016 edition of “Spot on Biotech Business” - the 7th annual compendium of NRW’s biotech business

Dear Reader,

Is biotechnological research and develop-ment of today still an important driver for the development of our global societies? Is biotech able to hold up to the expectations that were set during the past decades? Are we still getting answers to our major chal-lenges like climate change, ageing popula-tions or dwindling resources through inno-vative technologies and products? Or has biotech been outpaced by other technolo-gies or disciplines? When BIO.NRW Cluster Biotechnology hosted “German Biotech Days” – the country’s largest event of the industry – in April 2015 in Cologne, about 900 participants from academia, industry and politics together generated an impres-sive list of answers to these questions. The clear picture of a highly dynamic, innovative and potent business with all its various areas became obvious during the contribu-tions of the 150 speakers and in numerous intense discussions: making use of the lat-est information technologies, individualized treatments with refined diagnostics are becoming a reality; primary products like ethanol, polymers or rubber are obtained from renewable sources; a wide range of customized enzymes is filling up the toolbox of a growing bioeconomy; young companies from all across the country that develop innovative medical therapies or platform technologies are gaining more international attention.

Definitely – biotechnology delivers an-swers to the grand challenges and needs of our time and today it delivers more solutions than ever before. Unfortunately, that’s not the whole story: for over a decade, the bot-tleneck of (start-up) biotech business devel-opment has been the lack of available risk

landscape. To provide a similar overview of the academic side of biotechnology in NRW, BIO.NRW published the companion brochure “Spot on Biotechnology Science” of which the second edition is scheduled for release in early 2016.

Over the past year, BIO.NRW has strength-ened collaborations within the cluster and internationally via our established series of events that will continue in 2016 (for details please visit www.bio.nrw.de). For example, BIO.NRW will support BIO-Europe 2016 - Europe’s biggest partnering event in life sciences – taking place in Cologne in November. I invite everyone to take advan-tage of our offerings and to engage with our state’s extensive and excellent biotech com-munity, which is one of the leading biotech hotspots in Europe.

Dr. Bernward GarthoffCluster BIO.NRW

Representative for Biotechnology of the German State of North Rhine-Westphalia

6

BIO.NRW

© 2015/16, BIO.NRW “Spot on Biotechnology Business” www.bio.nrw.de

Print: Druck & Verlagshaus Mainz GmbH, AachenDesign and Layout: it’s FR!TZ

Picture Source: p. 4 © Martina Berg – Fotolia.comp. 8 © bogdanhoda – istockphoto.comp. 10 © Wavebreakmedia – istockphoto.comp. 12 © Jaroslav74 – istockphoto.comp. 14 © anyaivanova – istockphoto.comp. 16 © luchschen – istockphoto.comp. 18 © Wavebreakmedia – istockphoto.comp. 24 © Danil Chepko – istockphoto.comp. 34 © vadimguzhva – istockphoto.comp. 50 © Marcin Robert Balcerzak – istockphoto.comp. 58 © vlad teodor photography – istockphoto.comp. 62 © sofiaworld – istockphoto.comp. 68 © it’s FR!TZ (Heiko Fritz)

7

BIO.NRW

Content

Editorial ……………………………………………………………………………… 5

Spot on Biotechnology Business ………………………………… 9

Biotech Landscape …………………………………………………………… 9

Stimuli for Start-Up‘s ……………………………………………………… 9

Academic Biotech Research ………………………………………… 11

Biotech Business …………………………………………………………… 13

Competence Clusters …………………………………………………… 17

Industrial Biotechnology – CLIB2021 …………………………… 17

Pharmaceutical Biotechnology – BIO.NRW.red …… 19

From Mind to Market …………………………………………………… 19

Biotechnology Map of North Rhine-WestphaliaLife Science Technology Parks and Incubators …… 20

Biotechnology Map of North Rhine-WestphaliaDedicated and other biotechnologically active companies ……………………………………………………………………… 22

Company Directory 2015/2016 NRW

Non-specific Services …………………………………………………… 24

Health and Medicine (including Animal Health) …… 34

Industrial Biotechnology ……………………………………………… 50

Agrobiotechnology ………………………………………………………… 58

Bioinformatics ………………………………………………………………… 62

BIO.NRW Cluster Biotechnology North Rhine-Westphalia ……………………………………………… 64

Glossary …………………………………………………………………………… 66

OECD Definition ……………………………………………………………… 66

Organisation for Economic Co-operation and Development (OECD) …………………………………………………… 66

Biotechnology company ……………………………………………… 66

Dedicated biotechnology companies ……………………… 66

Other biotechnologically active companies …………… 66

Business Areas of Activity …………………………………………… 66

Contact BIO.NRW …………………………………………………………… 66

Sources, Literature, Links …………………………………………… 66

8

BIO.NRW

9

BIO.NRW

Spot on Biotechnology Business

Biotech Landscape

North Rhine-Westphalia (NRW) is at the heart of Europe. 150 million people – a third of the population of the European Union – live within a day’s drive of Düsseldorf, the state capital. 30 percent (i.e. EUR 196.6 billion in 2013) of the direct foreign investment that flows into Germany ends up in North Rhine-Westphalia, where some 18.000 international companies control their German and European opera-tions from. The state also is the number one exporter among Germany’s 16 federal states. With around EUR 625 billion, NRW generates 21.5 % of the German GDP, putting it clearly at the top of all German federal states. If NRW was classified as an independent exporting nation in its own right, it would rank 19th in the world in terms of size – just ahead of Turkey, Saudi-Arabia and Switzerland.1 With 17.6 mil-lion inhabitants of which 9 million live in the Rhine-Ruhr area, that lists among the top 30 metropolitan areas in the world – NRW is by far the most populous German state. Consequently, the state boasts the highest level of infrastructure within Germany includ-ing the country’s densest railway network and seven international airports. Handling more than 123 million tons of goods per year, Duisburg is the world’s largest inland port. Traditionally, North Rhine-Westphalia has been Germany’s most important location for the pharmaceutical and chemical industry. For the latter sector, about 32 percent of the country’s sales are generated in NRW (ranking 5th in the EU and 13th worldwide).2 Today the state has also developed into a life sciences hotspot: A good reason for many top-level biotechnology companies and research institutes to have their headquarters here.

Numerous successful start-up and spin-off companies are flourishing in NRW alongside a strong chemical and pharmaceutical industry that includes many well-known household names like Bayer HealthCare, Bayer CropSci-ence, Evonik, Henkel, Grünenthal, Johnson & Johnson or UCB. This business excellence is endorsed by a dense network of outstanding academic institutions, which focus on biotech-nology within a broad life sciences landscape. In addition, there is an equally rich and robust funding environment to support and promote the industry, including venture capital provid-ers and business development organizations. Biotechnology in NRW represents an active, multi-centric network, which is setting the pace for the powerful pulse of the state’s life science business. Meanwhile biotechnology is a maturing industry that expands rapidly. Its innovative technologies are applied to major industry branches serving health/medicine,

chemistry, food and environment. North Rhine-Westphalia has been developing its biotechnology hotspot since 1995. 20 years into the program, over 400 life science related companies are located here – among them 105 biotechnology enterprises including several global players (Figure 1). Major business areas covered are industrial, nano- and pharmaceuti-cal biotechnology, and there is a focus on ena-bling technologies and supporting services as well. Combining the strong technical expertise evolving from these areas has been the key driver for NRW as the state is pioneering the field of bioeconomy in Germany.

Stimuli for Start-Up‘s

Many of today’s successful young biotech companies started as university spin-offs. They took advantage of life science incuba-tors and technology centers, whose exist-ence can be pivotal for a start-up company. As catalysts for regional infrastructure and economic development, there are approxi-mately 60 such centers and incubators in the immediate vicinity of universities and basic research institutions in NRW. They support technology transfer all the way from mind to market. At the time of the editorial deadline of this brochure, a total of 149 biotech and life science related companies were incubated by 25 of these technology centers.3 You will find the respective locations of the centers and the number of biotech companies each of them hosts on the map on page 20. The services these start-up centers provide include renting affordable laboratory and office space, medi-ating business contacts, consulting on funding opportunities, and advising on either founding or relocating a firm. Business-plan competi-

Fig. 1: Life Science Company Landscape in North Rhine-Westphalia

~330 other life science related companies

16 other biotechnologically active companies

89dedicated

biotechnologycompanies

10

BIO.NRW

11

BIO.NRW

tions are offered as an additional chance for support. One technology park that deserves to find special mention here is BioCampus Co-logne, one of the largest of its type in Germany. It houses more than 23,000 square meters of laboratory and office space, and industrial production facilities on a site totaling more than 25 hectares. Company founders, young entrepreneurs and scientists all profit from NRW’s highly-networked biotechnology scene.

Academic Biotech Research North Rhine-Westphalia is offering Germany’s most comprehensive network of academic institutions consisting of internationally renowned Universities and Universities of Applied Sciences (72; 28 with life science activity), Max Planck Institutes (13; 8 with life science activity), Fraunhofer Institutes (14; 4 with life science activity), Helmholtz Institutes (3; 3 with life science activity) and Leibniz Institutes (11; 7 with life science activity). One quarter of all German students are tak-ing advantage of this excellent environment for science and education and are pursuing their studies in NRW. University centers can be found in Aachen, Bonn, Köln, Düsseldorf, Münster, Bochum, Essen, Dortmund, Biele-feld, and other cities in the state. In the area

of biotechnology, specializations in cell biol-ogy, (bio-) medicine, biochemistry, genomics, proteomics, metabolomics, molecular biology, systems and synthetic biology, analytics/microsystems, bioinformatics and process engineering are all on offer. For over a decade, NRW has been the leading German region in stem cell research and development with Mün-ster, Bonn and Köln as hotspots. In the field of plant genetics, the Max-Planck-Institute for Plant Breeding Research, Köln deserves to be called the “cradle of plant biotechnology” in Germany as the first plant transformation technologies were developed here. Two recent examples from Cologne emphasize the very

dynamic development of NRW as a research location: in May 2013 the all new research facilities of CECAD (Cluster of Excellence - Cel-lular Stress Responses in Aging-Associated Diseases) have been opened – an investment of EUR 85 million. In October 2013 the Max-Planck Society opened the new facility of the Max-Planck Institute for Biology of Ageing in immediate vicinity to the new CECAD building on the university campus. Both research cent-ers were designed in superior yet distinctive architecture and are equipped with cutting edge infrastructure and technology. They offer laboratory and office space for together more than 700 international scientists, staff and

Fig. 2: Top Regions in Biotechnology Patent Applications (Number of PCT Patents)

Fig. 3: Biotechnology Patent Development in NRW

1. San Jose-San Francisco-Oakland 15102. Boston-Worcester-Manchester 14223. New York-Newark-Bridgeport 10904. Washington-Baltimore-N.Virginia 8115. Tokyo 7926. San Diego-Carlsbad-San Marcos 7827. Los Angeles-Long Beach-Riverside 6138. Philadelphia-Camden-Vineland 5879. North Rhine-Westphalia 50613. Bavaria 37518. Baden-Württemberg 29429. Berlin 198

1600

1400

1200

1000

800

600

400

200

0

2

4 5 6

7 8

13

29

1

3

9

18

45004000350030002500200015001000

5000

patents pendig patents published

Nu

mb

er

1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

12

BIO.NRW

13

BIO.NRW

students. Along with the respective institutes of the University of Cologne and the University Hospital as well as the DZNE (German Center for Neurodegenerative Diseases) in Bonn, Cologne has been developed into a world-wide unique competence center for ageing research. About one hour east of Cologne, Europe’s most innovative technology campus is currently taking shape: covering 800.000 square meters, “Campus Melaten” of the RWTH Aachen University will house up to 11 technology clusters, among them the “cluster biomedical technology” and take up invest-ments of EUR 1 billion. BIO.NRW offers detailed

Fig. 4: Size of Dedicated Biotechnology Companies (Number of Employees)

Table 2: Number of dedicated biotech com-panies

Table 1: Key Figures for the Biotechnology Industry of North Rhine-Westphalia

89 dedicated biotechnology companies in 2014 (87 in 2013, 84 in 2012 )

2012 2013 2014 2012 2013 2014

Number of employees* 3,758 (n=67) 3,680 (n=67) 3,758 (n=68 ) 3,900 3,900 3,950

Turnover* EUR 1.34 bn (n=32) EUR 1.27 bn (n=29) EUR 1.32 bn (n=25) EUR 1.7 bn EUR 1.7 bn EUR 1.75 bn

R&D expenditure* EUR 190 m (n=30) EUR 214 m (n=29) EUR 241 m (n=22) EUR 220 m EUR 230 m EUR 250 m

based on survey biotechnologie.de based on survey & own estimates

information about the academic life science landscape in NRW in its compendium “Spot on Biotechnology Science. This brochure is composed in a similar manner like „Spot on Biotechnology Business“ and presents a total of 184 profiles of research institutes, centers and facilities in NRW. Its second issue will be released in early 2016.

Biotech Business

According to the “OECD Biotechnological Statistics 2009” report (which – except for limited “indicator” updates - still is the latest published detailed study in the field by the

* based on the 04/2015 company survey and additional data ; n means number of companies giving indications

below 10 10-49 50-99 100-249 more than 250

Health / Medicine Non-specific services Industrial biotechnology Agrobiotechnology Bioinformatics

48.3%

5.6% 3.4% 2.2%

40.4%

Business Year NRW / %* Germany

2007 53 / 10,7 496

2008 61 / 12,2 501

2009 68 / 12,8 531

2010 71 / 13,2 538

2011 77 / 14 552

2012 84 / 14,9 565

2013 87 / 15,3 570

2014 89 / 15,4 579* % of Germany total

40 / 44.9%

28 / 31.5%

15 / 16.9%

4 / 4.5% 2 / 2.2%

Fig. 5: Areas of activity

OECD), North Rhine-Westphalia is Europe’s most innovative biotechnology region: It generates more biotech PCT patent applica-tions than any other European region (Figure 2).4 The development of biotech innovations from NRW has been constantly increasing: 4,121 biotech patents have been filed in total between 1996 and 2010 by NRW biotech com-panies and research facilities of which 4,118 have been published (Figure 3).5 Based on the OECD definition (see page 66), 89 dedicated biotech companies were operating in NRW

14

BIO.NRW

15

BIO.NRW

in 2014. Their activities were complemented by 16 other companies with a biotechnologi-cal commitment, mostly global player in the field of pharmaceuticals, chemicals or seed production. Since these companies are active in many diverse areas, their biotech related business figures cannot be calculated exactly and are not included in the following statistics. The real economic impact of biotechnology in NRW is therefore higher than these statistics reveal. The following analysis is performed in cooperation with “biotechnologie.de” (using data from their annual company survey)6 and focuses on dedicated biotechnology compa-nies exclusively. These companies are at the in-novative core of biotechnological research and development. The business figures of the 89 NRW dedicated biotech companies are set into comparison with the 579 German dedicated companies and the 490 German companies without the NRW contribution, respectively. In NRW about 3,900 people (of about 19,000 nationwide) – more than in any other German federal state – were employed by dedicated biotech companies in 2014 and generated a turnover of approximately EUR 1.32 billion (Ta-ble 1). According to the national company sur-vey by “biotechnologie.de” the NRW dedicated biotechnology companies generated about 44% of the German annual turnover (EUR 3.03 billion) in this sector which is at the same level as in 2013. Thus, the biotech industry in NRW is - to a large extend - responsible for the economic impact of the German biotech busi-ness as a whole. EUR 241 million – a significant annual increase by 12.6% compared to 2013 and 25.2% compared to 2012 (EUR 214 and EUR 190 million) – was reinvested into R&D projects. In the same time, R&D reinvestments in Germany increased by only 2.1% which is solely resulting from the increase in NRW. The development of this key business figure under-lines that the investments by the dedicated biotech companies in NRW are persistent and will advance the future market position of NRW biotech. Together, NRW biotech firms

Indication Number of Products

Infectious and parasitic diseases 18

Neoplasms / cancer / oncology 17

Other 16

Diseases of the nervous system 9 Skin and subcutaneous tissue 7

Diseases of the blood and blood-forming organs; immune disorders 2

Musculoskeletal system and connective tissue 2

Respiratory 2

Mental and behavioural disorders 2

Symptoms, signs abnormal clinical and laboratory findings, not elsewhere classified 1

Cardiovascular 1

Digestive system 1

Total 78

Fig. 6: Drug Development Pipeline by Indication

are placing the highest investments for R&D of innovative products – nationwide. Overall, the proportional expenditure for R&D of 18.3% of the annual turnover is more than 5 times higher than the mean of all other businesses in Germany.7 The figures reflect that biotech-nology as a business sector is in the process of maturation: after several years with an unchanged age structure the average biotech company in NRW has been in operation for 11.2 years (10.4 in 2013). However, important factors that reduce the average company age in the industry are new foundations and acquisitions of successful ventures by global players. The employee structure remains almost unchanged: about 89 percent of the

biotechnology companies in NRW employ fewer than 50 people and 94 percent of the companies have less than 100 employees, respectively (Figure 4). After venture capital (VC) investments of EUR 9.7 million in 2012 and 14.1 million in 2013, VC for NRW biotech companies doubled in 2014 to EUR 28.5 mil-lion. With two new dedicated and one new other biotech-active companies in NRW in 2014 the state’s biotech scene continues to be the fasted growing one in Germany count-ing 12 new companies within the past three years (Table 2). In almost all other regions in Germany except for Baden-Württemberg but including Bavaria the number of dedicated biotech companies is almost stagnant. Con-

16

BIO.NRW

17

BIO.NRW

sequently, after the Bavarian clusters (104 + 17) and close to Baden-Württemberg (92 + 16), the highest density of companies in Germany is located in NRW (89 + 16). In 2014 31.5 per-cent (33.3 in 2013) of the biotech companies in North Rhine-Westphalia were active in multiple branches (Figure 5). These biotechnology companies with “nonspecific business activi-ties” include service providers and suppliers for the industry. Germany’s two largest biotech companies, QIAGEN GmbH and Miltenyi Biotec GmbH used to be listed here. As QIAGEN has developed into the field of medical applica-tions, meanwhile the company is accounted as a dedicated biotech company in the „health-medicine“ sector in this survey. QIAGEN began as a spin-off from the University of Düsseldorf in 1984. Today, the company employs more than 4,400 experts at 30 sites worldwide, and has become the leading provider of sample technology and a top player in molecular diagnostics. Through a number of strategic moves QIAGEN today is one of the leading companies in biomarker discovery and devel-opment (i.e. companion diagnostics), which is the basis for the company’s redirection to the health business. Based on the invention of a magnetic cell separation technology, Miltenyi Biotec was founded 1989 in Bergisch Gladbach near Cologne. Since then, the company has expanded to 1,400 employees worldwide who produce and market over 1,400 products for the global biomedical research community. It is remarkable that this success has been solely achieved by generic growth. The majority of dedicated NRW biotech companies (44.9%; 42.5% in 2013) are active in the field of health and medicine developing new drugs or diag-nostics within the pharmaceutical sector. At the time of the editorial deadline of this brochure the dedicated biotech companies in the field of health and medicine had developed a drug pipeline of in total 78 products and product candidates, increasing the 2015 pipeline by 5 % compared to 2014 and 20% compared to 2013. The detailed distribution by indication lists

Fig. 7: Drug Development Pipeline by Phase

“infectious and parasitic diseases” (18) and “neoplasms/cancer/oncology” (16) as top cat-egories (Figure 6). Therapeutics for “diseases of the nervous system” dropped from 15 in 2014 to 9, followed by 7 products for “skin and subcutaneous tissues”. The pipeline includes 17 therapeutics (21.8%) in the clinical phases I to III (14 in 2014, Figure 7).8 6 products are on the market and 31 preclinical drug candidates are in development contributing to the growth of the drug development pipeline compared to 2014 (24).

With 16.9 percent (17.2% in 2013) – com-pared to 9.8 percent of companies in this sector across Germany – industrial biotech-nology remains a characteristic strength of NRW. The underlying classification refers to companies that develop enzymes, biomateri-als or bioprocesses, which can be applied to facilitate or enable large-scale production in the chemical industry. The NRW-based compa-nies Henkel and Evonik have been pioneering industrial biotechnology worldwide and are still its pacesetters.

Competence Clusters

Besides the large number of biotech com-panies, which have specialized in enabling technologies, two main fields of activity

characterize the biotechnology landscape in North Rhine-Westphalia: Industrial Biotech-nology and Pharmaceutical Biotechnology.

Industrial Biotechnology – CLIB2021

CLIB2021 (Cluster Industrial Biotechnoloy 2021) is an international open innovation cluster of large companies, SMEs, academic institutes and universities as well as other stakeholders active in biotechnology and bioeconomy as a whole. The cluster comprises a share of about 30% international members. The overall goal of CLIB2021 is to network stakeholders along and across value chains and to identify new oppor-tunities. The cluster mainly focuses on indus-trial biotechnology to provide solutions for the chemical industry: raw materials, biocatalysts, processes, products and technologies that result in monomers, fine chemicals or in their functionalization. Pertinent project areas are identified by the CLIB2021 team in conjunction with members in an iterative process. CLIB2021 is a non-profit association, with its members shaping the cluster’s interests and activities. The cluster coordinates several associated programs which cover different aspects of bioeconomy and invites members to become involved, bring in their own ideas and to gener-ate a real benefit for their companies or institu-

On the Market6

n/a16

Lead optimization1

Preclinical31

Phase III5

Phase II5 Phase I

7

Discovery7

18

BIO.NRW

19

BIO.NRW

tion. To this end, CLIB2021 organizes a number of events throughout the year: the annual CIC (CLIB international conference), forum events, topic-specific workshops, dedicated small partnering meetings and visits to partners, sites or meetings in Germany and abroad.

The CLIB-Graduate Cluster (CLIB-GC) was established in 2009 by the universities of Bielefeld, Dortmund, Düsseldorf together with the Jülich Research Center and addresses key areas in biotechnological research rang-ing from genome and metabolome analysis, protein expression and biocatalysis to product purification. Furthermore, CLIB-GC brings together different academic groups and thus provides a critical mass to develop new biotechnological processes and products. Consequently, CLIB2021 also seeks to provide competence in intellectual property (IP) and legal issues, techno-economic evaluation, market access as well as to provide ways for SMEs to access industrial sites in its network.

In NRW, CLIB2021 is coordinating the regional innovation network (RIN) “Stoffströme”, which seeks to improve exploitation of biomass, wastes and side streams in the region. This action is funded by NRWs Ministry of Innova-tion, Science and Research (MIWF). Together with partners in Germany, Flanders and the Netherlands, CLIB2021 is currently building the BioInnovation Growth mega-Cluster (BIG-C). The establishment of BIG-C is supported by the German Federal Ministry of Education and Research (BMBF) through a 5-year, 4 million Euro project, starting in 2016.

Pharmaceutical Biotechnology – BIO.NRW.red

In the last decades, major milestones in medicine and healthcare have been achieved through pharmaceutical (“red”) biotechnol-ogy, namely in the development of drugs, vaccines and diagnostics. In 2014, 287 of all 579 dedicated German biotech companies (49.6%) were active in the field of red biotech-

nology. 51 of the individual firms that develop therapeutics, 3 in addition to 2013, have one or more products in the clinical pipeline (phase I-III). Compared to 2013 the number of drug candidates in clinical development rose by six, up to a total of 97. Five preclinical projects took the step towards clinical research and 9 active substances were recorded in phase III.6

More than two-third of the German biotech industry turnover (EUR 2.08 billion) was generated by the dedicated biotechnology companies active in the field of health and medicine in 2014.6

From the biopharmaceutical point of view 2014 was another strong year. 14 out of 47 newly approved drugs (30%) were biopharmaceuticals. Their sales in Germany increased by 7% in real terms and reached a volume of about EUR 7.5 billion, which corre-sponds to 22.0% of the total pharmaceutical market in 2014. Indications with a high medi-cal need are still Immunology and Oncology and the increase in the biopharmaceutical turnover was most significant in these areas (Immunology increased by 24% and Oncol-ogy increased by 19%).9

For more than a century, NRW has been the heartland of Germany’s pharmaceutical industry and has an exceptional standard in biotechnological and medical education. This advantage, combined with the enormous market potential of biopharmaceuticals, gave reason for BIO.NRW’s strategic initiative in the field of red biotechnology called BIO.NRW.red. Its starting point was the compe-tition “Bio.NRW” 2009, a call for projects announced by NRW’s Ministry of Innovation, Science and Research (MIWF) to support the formation of consortia between academia and biotech companies. The focal areas of the successful projects were: development of drugs (biologicals and small molecules), generation of new methods in diagnostics, es-tablishment of biomarkers and introduction of new biopharmaceutical processes – mainly based on cell cultures technology.

Since 2009 additional Calls for public fund-ing in the field of red biotechnology were an-nounced by the MIWF. “PerMed.NRW” (by the end of 2010), focused on personalised medi-cine and “Translational Stem Cell Research” (finished in June 2014) continue to effectively boost the BIO.NRW.red initiative.

By the end of 2014 a new series of com-petitions were published by NRW’s state government, adopting a “two-rounds funding model”. Focussing on translational research in eight so-called “main markets” (NRW Leitmarkt-Wettbewerbe), the call for projects in Life Sciences (first round ended in August 2015) includes topics like diagnostics, drug development, and prevention. Members of the new successful consortia will expand the sus-tainable BIO.NRW.red network that connects major contributors to medicine, healthcare, the pharmaceutical industry and red biotech-nology in the state.

From Mind to Market

This chapter provides an overview of 89 of the dedicated and 16 of the other biotechno-logical-active companies from North Rhine-Westphalia as classified following the OECD guidelines (page 66). For convenience, the companies are grouped in five areas accord-ing to their main business:

Non-specific Services Health and Medicine

(including Animal Health) Industrial Biotechnology Agri/Agrobiotechnology Bioinformatics

For a more comprehensive directory that includes all life science and life science related companies in NRW, please visit our company database at www.bio.nrw.de/en/company_database. BIO.NRW invites you to discover North Rhine- Westphalia‘s biotech-nology community!

20

BIO.NRW

Q

Bonn

Q Witten

Q Gronau

Q Hilden

Q

Essen

Q Langenfeld

Q Troisdorf

Q Rheda-Wiedenbrueck

Q Nettetal

Rhine

Rhine

Ruhr

The Netherlands

Belgium Germany

Lippe

Ems

Weser

Q Wuppertal

4

Q Bielefeld

Q Bergisch-Gladbach

Q MünsterQ Ascheberg

3

3

11

3

4

3

6

8

79

2

14

15

12

18

Q Aachen

1

DortmundQ

4

Q Köln4

3

Q Kempen

Q JülichBaesweiler

Q

Düsseldorf Q

Q Bönen3

1

Bochum Q

Marl Q

EssenQ

Biotechnology Map of North Rhine-WestphaliaLife Science Technology Parks and Incubators

Herzogenrath Q

Rheinbach Q

54

Q

Witten

Q Monheim

1

21

BIO.NRW

Name City Companies* Homepage

1 Zentrum für Bio-Medizintechnik (ZBMT) Aachen 2 www.agit.de

2 INCA Technologiezentrum GmbH Ascheberg 3 www.inca-technologiezentrum.de

3 its-Internationales Technologie- und Service-Center Baesweiler Baesweiler 8 www.its-center.de

4 Technologiepark Bergisch-Gladbach Bergisch-Gladbach 4 www.tbg.de

5 Technologiezentrum Bielefeld Bielefeld 3 www.technologiezentrum-bielefeld.de

6 BMZ - BioMedizinZentrum Bochum Bochum 7 www.bmz-bochum.de

7 TZR - Technologiezentrum Ruhr Bochum 3 www.chip-tzr.de

8 Bio-Security Bönen 9 www.bio-security.de

9 BMZ - BioMedizinZentrum Dortmund Dortmund 18 www.bmz-do.de

10 LSC - Life Science Center Düsseldorf Düsseldorf 15 www.lsc-dus.de

11 Essener Technologie- und Entwicklungs-Centrum ETEC GmbH Essen 1 www.etec.de

12 TPH Technologie Park Herzogenrath Herzogenrath 6 www.tph.de

13 Technologiezentrum Jülich Jülich 3 www.tz-juelich.de

14 Technologie- und Gründerzentrum Niederrhein GmbH Kempen 4 wwwtzniederrhein.de

15 BioCampus Cologne Grundbesitz GmbH & Co. KG Köln 14 www.biocampuscologne.de

16 RTZ - Rechtsrheinisches Technologie- und Gründerzentrum Köln Köln 4 www.rtz.de

17 TechnologiePark Köln Köln 3 www.tpk.de

18 Technologie- und Chemiezentrum Marl GmbH Marl 1 www.technomarl.de

19 Creative Campus Monheim Monheim 11 www.cc-monheim.de

20 Technologieförderung Münster GmbH Münster 12 www.technologiefoerderung-muenster.de

21 CeNTech - Center for Nanotechnology Münster 4 www.centech.de

22 Gründer- und Technologiezentrum Rheinbach Rheinbach 3 www.wfeg-rheinbach.de

23 Forschungs- und Entwicklungs-Zentrum Witten GmbH Witten 5 www.fez.de

24 ZBZ - Zahnmedizinisch Biowissenschaftliches Forschungs- und Entwicklungszentrum Witten GmbH Witten 4 www.zbz-witten.de

25 Technologiezentrum Wuppertal W-tec GmbH Wuppertal 1 www.w-tec.de

Total: 25 148

* Life Science Companies

22

BIO.NRW

Rhine

Rhine

Ruhr

The Netherlands

Belgium Germany

Lippe

Ems

Weser

Q Bielefeld

Q

Bonn

Q

NettetalQ Witten

Q Gronau

Q

Bochum

Gelsenkirchen Q

Q HildenDüsseldorf Q

Moers Q

Q Marl

Q Bergisch Gladbach

Q Leopoldshöhe

Q Bad Salzuflen

Q TroisdorfQ St. Augustin

Q Aachen

Q Rheda-Wiedenbrück

Q JülichQHerzogenrath

BaesweilerQ

Q Erkrath

MünsterQ

Q Köln

Q Wuppertal

Osnabrück Q

Niederkassel Q

Biotechnology Map of North Rhine-WestphaliaDedicated and other biotechnologically active companies

Q Dortmund

Q LeverkusenQ Langenfeld

Q Ascheberg

Essen Q

BergkamenQ

Mönchengladbach QMonheim Q

Neuss Q

23

BIO.NRW

1 List of dedicated biotechnology companies in the fiscal year 2014 1 2 OECD Definition page 66 3 including company sites in NRW that are not headquarters and are therefore not accounted as NRW-based companies in the annual study by “biotechnologie.de”

Dedicated companies1, 3

A2M Pharma GmbH Monheim p. 35Affectis Pharmaceuticals AG Dortmund p. 35AgroProtect GmbH Aachen p. 57AiCuris GmbH & Co. KG Wuppertal p. 35Algiax Pharmaceuticals GmbH Erkrath p. 36arrows biomedical Deutschland GmbH Münster p. 36ARTES Biotechnology GmbH Langenfeld p. 25Autodisplay Biotech GmbH Düsseldorf p. 51AVENTRA GmbH Osnabrück p. 25Axiogenesis AG Köln p. 36AYOXXA Biosystems GmbH Köln p. 25Baliopharm GmbH Jülich p. 37BBT Biotech GmbH Baesweiler p. 26BIBITEC Gesellschaft für Prozessentwicklung mbH Bielefeld p. 26BioCheck GmbH Münster p. 37Biofrontera AG Leverkusen p. 38Bio-Mar Düsseldorf BioSolveIT GmbH Sankt Augustin bitop AG Witten p. 51BSV Bioscience GmbH Baesweiler p. 51CAP-CMV GmbH Köin p. 38Carpegen GmbH Münster p. 38CellAct Pharma GmbH Dortmund p. 39CellSystems Biotechnologie Vertrieb GmbH Troisdorf p. 26Cevec Pharmaceuticals GmbH Köln p. 39Charles River Biopharmaceutical Services GmbH Erkrath p. 27ChemBiotech Münster p. 27Chimera Biotec GmbH Dortmund p. 27CIBUS Biotech GmbH Rheda-Wiedenbrück p. 28Cilian AG Münster p. 39CIRES cell & immune research services Dortmund p. 40Colbourne Pharmaceuticals GmbH Niederkassel p. 40Cube Biotech GmbH Monheim p. 28Cysal GmbH Münster p. 52DIREVO Industrial Biotechnology GmbH Köln p. 52Epivios GmbH Düsseldorf evocatal GmbH Monheim p. 52GEN-IAL GmbH Troisdorf p. 28IIT an der Universität Bielefeld GmbH Bielefeld p. 29IMAX Discovery GmbH Dortmund p. 53IMD Natural Solutions GmbH Dortmund p. 54InfanDx AG Köln p. 41Lead Discovery Center GmbH Dortmund p. 41Life & Brain GmbH Bonn p. 42Lonza Cologne GmbH Köln p. 29m2p-labs GmbH Baesweiler/Aachen p. 54Matricel GmbH Herzogenrath p. 42MBBL Dr. Bartling GmbH Bielefeld Medical Adhesive Revolution GmbH Aachen p. 42MetaVi Labs GmbH Witten p. 43miacom diagnostics GmbH Düsseldorf p. 43MILTENYI BIOTEC GmbH Bergisch Gladbach p. 29MLM Medical Labs GmbH Mönchengladbach p. 43Morphoplant GmbH Bochum p. 44multiBIND biotec GmbH Köln p. 54

MykoMax GmbH Wuppertal p. 60NEO New Oncology AG Köln p. 44NEUWAY Pharma GmbH Bonn p. 44Nexigen GmbH Köln p. 45PAIA Biotech GmbH Köln p. 30PAION AG Aachen p. 45Pharmedartis GmbH Aachen p. 46Phytowelt GreenTechnologies GmbH Nettetal p. 60PlasmidFactory GmbH & Co. KG Bielefeld p. 30Protagen AG Dortmund p. 46Protagen Protein Services Dortmund p. 30Protectimmun GmbH Gelsenkirchen p. 46PS Biotech GmbH Aachen p. 31QIAGEN GmbH Hilden p. 47Rhein Biotech GmbH (Dynavax Europe) Düsseldorf p. 47Ridom GmbH Münster p. 63Rigontec GmbH Bonn p. 47Saaten-Union BIOTEC GmbH Leopoldshöhe p. 61SanguiBioTech GmbH Witten p. 48SAW Instruments GmbH Bonn Senzyme GmbH Troisdorf p. 55SeSaM-Biotech GmbH Aachen p. 55Sibion Biosciences GmbH Bonn SIT Soft Intelligent Therapeutics GmbH & Co KG Dortmund p. 48Sividon Diagnostics GmbH Köln p. 48Soluventis GmbH Bochum p. 31Squarix GmbH Marl p. 31Syntab Therapeutics GmbH Aachen p. 49Sysmex Partec GmbH Münster p. 32TaconicBiosciences GmbH Köln p. 32Transimmune AG Düsseldorf p. 49vivo Science GmbH Gronau p. 32W42 Industrial Biotechnology GmbH Marl p. 56WeissBioTech GmbH Ascheberg XanTec bioanalytics GmbH Düsseldorf p. 33Xell AG Bielefeld p. 33

Other biotechnologically active companies2, 3

BASF Personal Care and Nutrition GmbH Monheim Bayer CropScience AG Monheim p. 59Bayer HealthCare/ Bayer Pharma AG Bergkamen p. 37Bayer Technology Services GmbH Leverkusen Evonik Industries AG Essen p. 53German Seed Alliance GmbH Köln p. 59Grünenthal GmbH Aachen p. 40Henkel AG & Co. KGaA Düsseldorf p. 53Janssen-Cilag GmbH Neuss p. 41MEDIWISS Analytik GmbH Moers Monsanto Agrar Deutschland GmbH Düsseldorf p. 60Octapharma GmbH Langenfeld Pharma Waldhof GmbH Düsseldorf p. 45Syngenta Seeds GmbH Bad Salzuflen p. 61Taros Chemicals GmbH & Co. KG Dortmund p. 55UCB GmbH Monheim p. 49W. von Borries-Eckendorf GmbH & Co. KG Leopoldshöhe p. 61

24

Non-specific Services

25

BIO.NRW non-specific services

Name

Address

Postal Code/CityFonFax

E-MailInternet

EmployeesFounded (year)

Name

Address Postal Code/City

FonFax

E-MailInternet


ARTES Biotechnology GmbH

Elisabeth-Selbert-Str. 940764 Langenfeld

+49 2173 27587-0+49 2173 [email protected] www.artes-biotechnology.com22 2002

ARTES Biotechnology is an independent technology provider for the pharmaceuti-cal industry. Our business focus is on: • vaccine development (VLP technology) • process development of biopharma-

ceuticals• transfer of biosimilar processes Our technologies have resulted in innovative products marketed worldwide. WHO recom-

mendation, international registration, EMA resp. FDA approval and GRAS certification are achieved in international collaborations.

Expression platforms include high yield yeasts and E. coli system for efficient pro-tein production. Our unique chimeric virus like particle (VLP) platform METAVAX® is best suited for the development of highly immunogenic vaccines in human and ani-mal health.

Our proprietary technologies ensure freedom-to-operate and reliable, com-petitive production of innovative targets marketed worldwide.

AVENTRA GmbH

Siemensstraße 42Biosecurity-Kompetenzzentrum für biologische Sicherheit59199 Bönen+49 5405 505-900+49 5405 505-910 [email protected]

AYOXXA Biosystems GmbH

Nattermannallee 150829 Köln

+49 221 222529-0+49 221 222529-11 [email protected]

332010

Name


FonFax

E-Mail Internet


AVENTRA GmbH is an independent com-pany focussed on the development and ap-plication of innovative diagnostic services. The main focus points are related to food safety, medical applications and expertise in quality management (QM) systems. We offer QM solutions specifically tailored for the needs of our customers including probe collection, diagnostic test programs,

AYOXXA Biosystems GmbH, an international biotech company based in Cologne (Ger-many), Boston (USA) and Singapore, has de-veloped LUNARIS™ the proprietary technol-ogy platform for multiplex protein analysis. LUNARIS™ BioChips enable researchers to perform simultaneous detection of multiple biomarkers in very small sample volume.

consulting and training of customer staff. To achieve this, our team displays a wide range of expertise in microbiological, biochemical and medical diagnostics. Our laboratories with the safety level L3** are equipped with state-of-the-art technology, which guarantees a safe, rapid and efficient performance of diagnostic services. Of course, we hold all the necessary qualifica-tions and certificates (DakkS certificate D-PL-14537-01-00).

Founded in 2010, AYOXXA is a biotech spin-off company of the National University of Singapore (NUS).

In September 2015, AYOXXA introduced LUNARIS™ 6-Plex Cytokine Kits to analyze prominent biomarkers that are important in inflammation and in immune regulation in human and mouse.

Together with a sample volume down to 3 µL, an increased assay robustness, and using fluorescence readout, AYOXXA will innovate biomedical research, pharmaco-logical screening and preclinical diagnostics development.

26

BIO.NRWnon-specific services

Name


FonFax

Internet


Name


FonFax

E-Mail Internet


BIBITEC GmbH

Universitätsstr. 2533615 Bielefeld

+49 521 106-6326 +49 521 106-156233 www.bibitec.de

102001

Name


FonFax

E-Mail Internet

Founded (year)

CellSystems Biotechnologie Vertrieb GmbH

Langeler Ring 553842 Troisdorf

+49 2241 25515-0 +49 2241 25515-30 [email protected] 1992

Since its formation CellSystems® has been a reliable partner for the life science community. CellSystems offers highly so-phisticated research products, including EU validated 3D in vitro skin models for research and toxicology assays that were developed and are produced at our onsite laboratories. Additionally, CellSystems offers a wide range of contract services.

In 2010, we opened our new clean room laboratories to meet the growing demands for various 3D tissue models and services. Today, our portfolio comprises a wide range of products for cell biology research and in vitro toxicology studies.

CellSystems is certified ISO 9001:2008.

BIBITEC Gesellschaft für Prozessentwick-lung mbH is specialized in the production and purification of proteins (e.g. hor-mones, mAbs) derived from mammalian cell cultures.

One major achievement was an eryth-ropoietin (EPO) project that involved the process development and the GMP-compliant production of an EPO biosimilar for use in phase III clinical trials.

The entire production and purification process was successfully transferred for large-scale production leading to one of the first successful approvals of a biosimi-lar in Europe.

In 2012 BIBITEC became part of Nord-mark Arzneimittel GmbH & Co. KG, Uetersen. In cooperation with Nordmark and other validated partners BIBITEC pro-vides all activities from “gene to product” including cell line and process develop-ment, GMP production, fill-and-finish and analytics.

BBT Biotech GmbH

Arnold-Sommerfeld-Ring 2852499 Baesweiler

+49 2401 93310-0+49 2401 [email protected]

301999

BBT Biotech GmbH produces freeze-dried viable bacteria (probiotics like lactobacilli, bifidobacteria, yeasts) and metabolites not only in bulk but also in finished dosage forms to the pharmaceutical and health-food industriy.

The fermenter capacity is up to 18.000 l. The downstream process is based on sepa-

rators, filtration systems, chromatography and freeze dryers. On the basis of individual needs BBT Biotech GmbH also offers active pharmaceutical ingredients like thrombo-lytics (streptokinase, urokinase), fertility hormones (HCG, HMG, FSH), inhibitors (Aprotinin, UTI) and others (Hyaluronidase, Corticotrophin).

http://www.cellsystems.de

27


Name


FonFax

E-Mail Internet


Name

Address

Postal Code/City

FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


ChemBiotech

Center for NanotechnologyHeisenbergstr. 11 48149 Münster

+49 251 53406-505+49 251 [email protected]

91999

ChemBiotech owns outstanding com-petence in the syntheses, modification and characterization of a diversity of nu-cleosides, nucleotides and DNA building blocks (phosphoramidites). ChemBiotech was founded in 1999 and is endemic in the research and development of nucleic acid chemistry. The highly trained staff

of ChemBiotech with a broad experience in nucleoside chemistry guarantees for high quality products, delivery in time and personalized R&D services.

We cooperate with industrial and sci-entific institutions and perform contract synthesis. ChemBiotech uses its strong competence for own R&D projects and to the benefit of our customers. Our syn-thetic expertise provides solutions for your chemical and biological demands in nucleic acid, carbohydrate, and heterocy-clic chemistry.

Chimera Biotec GmbH

Emil-Figge-Str. 76a44227 Dortmund

+49 231 9742-840 +49 231 9742-844 [email protected]

20 2000

Chimera Biotec is the leading provider of ultra sensitive immunoassay development and bioanalytical sample testing. Chimera provides customized services as well as target quantification based on in house assays. Chimera Biotec manufactures and markets ultra sensitive Immuno-assays for pharmacokinetics, pharmacodynam-

ics, immunogenicity assessment, stability testing and biomaker quantification.

Charles River Biopharmaceutical Services GmbH

Max-Planck-Str. 15a40699 Erkrath

+49 211 9255-300+49 211 [email protected]

Charles River Biopharmaceutical Services GmbH is a leading contract service or-ganization providing innovative and tailor-made solutions for the quality control of biopharmaceuticals.

We operate in full compliance with the GMP/GLP standards. Our testing facilities in Erkrath and Köln, Germany are part of a

global scientific network offering services that span the entire drug development process. This allows us to provide our clients with more flexibility, experience and expertise to maximize resources and optimize results based on their specific program needs.

Our services include: cell bank testing; analysis and clearance validation of con-taminants and impurities (residual DNA, host cell proteins and endotoxins); safety studies for viruses and prions; charac-terization of the final product, lot release testing; bioassays and stability studies.

28


Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Cube Biotech GmbH

Alfred-Nobel-Str. 1040789 Monheim

+49 2173 99373-0+49 2173 [email protected]

102012

Cube Biotech is a provider for protein ex-pression, purification, and crystallization services with a focus on the pharmaceuti-cally relevant class of membrane proteins.

Our services are complemented by affinity tag-based and protein-specific chromatography matrices to offer a unique solution.

Dedicated products for protein purifica-tion and membrane protein crystallization

are manufactured in-house and sold to scientific labs.

Main activities of the CIBUS Biotech GmbH are the development and application of molecular analyses for the examination of processed food, feed, or their single com-ponents as well as other products from pharmacological, cosmetic, paint or paper

industry. Fokus is analysis and product de-velopment to identify e.g. animal species, species of plants, GVO, allergens.

CIBUS Biotech GmbH

Amselweg 133378 Rheda-Wiedenbrück

+49 5242 40556-0+49 5242 40556-270 [email protected]

72001

Name


FonFax

E-Mail Internet


GEN-IAL GmbH is a specialist laboratory for DNA based food and feed analyses. GEN-IAL offers services and kits for GMO-, allergene- and animal identity analyses as well as bacteria- and yeast detection and differentiation. We offer training in PCR, contract research, several kits for DNA-extraction, PCR-kits for beer/wine spoilage bacteria and yeast, pathogenes (Salmo-

nella, Listeria, Campylobacter, Legionella), genetically modified organism (GMO), allergenes, plant and animal-identity. The laboratory is accredited (DIN EN ISO/IEC 17025) and official cross checking labora-tory. We are member in the German official working group for method development for GMO detection and quantification. We are listed laboratory for the American NON-GMO- Project.

New: Capturing of microorganism by poly-mer technology

GEN-IAL GmbH

Heuserweg 13-1553842 Troisdorf

+49 2241 252-2980+49 2241 [email protected]

101998

29


Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Name

Address

Postal Code/CityFonFax

E-Mail Internet


The Institut für Innovationstransfer GB Biotech (IIT Biotech) offers integrated genomic services. Since some years the main provided service is the ’next generation sequencing’.

The high-throughput techniques performed by Illumina HiSeq and MiSeq or by IonTorrent PGM can be offered combined with a power-ful lab & bioinformatic pipeline providing full service tasks like genomic assembly, gap closure and annotation.

Furthermore we offer individual solutions for the bioinformatic evaluation of project data. This includes construction of draft-genomics, storage/care of genome projects, analysis in resequencing and metagenomics and development/customization of analysis-software.

Lonza Cologne offers products for various everyday uses, such as disinfectants and detergents in hospitals or pool and spa areas, in pesticides against snails (met-aldehyde), in sports and energy drinks (vitamin B3, L-Carnitine) or in body lotions as emulsifying agents.

At the BioCampus Cologne, Lonza’s Bioscience Solutions staff develops and commercializes non-viral gene transfer

products for primary cells and hard-to-transfect cell lines. With Lonza’s Nucleo-fector™ Technology, the functionality of different genes can be analyzed in biologi-cally relevant cell types. These results help identify possible new pharmaceuticals and therapies, for example to fight cancer or cardiovascular diseases.

One of the latest additions to Lonza’s portfolio is the CytoSMART™ System, which enables researchers to monitor their cell culture remotely at any time.

Lonza Cologne GmbH


+49 221 99199-464 +49 221 [email protected]/research

1041998

Miltenyi Biotec GmbH

Friedrich-Ebert-Str. 6851429 Bergisch Gladbach

+49 2204 83066-540 +49 2204 8519-7 [email protected] www.miltenyi.tv1,4001989

Miltenyi Biotec, is a diversified biotechnology group of companies with a business focus on cellular technologies. M.B. produces and mar-kets state-of-the-art products and technolo-gies for cell separation, cell biology, related molecular biology applications. M.B. focuses on stem cell isolation, immune therapies, tis-sue replacement, with devices and biological

reagent kits for clinical and research use. Miltenyi Biotec also offers in cooperation with nanoPet pharma preclinical imaging agents – the Viscover™ Imaging portfolio. Another asset recently included into the program is lentiviral technology for cell and gene therapy applications. The CliniMACS® Technology al-lows clinicians to separate specific cell types to cure particular diseases. Acquiring OWL biomedical, Inc., Miltenyi Biotec has com-pleted its portfolio by microchip-based cell sorting systems using fully-closed cartridges in an easy-to-use-format, applicable to the research and clinical cell therapy markets.

IIT BioTech - Institut für Innovationstransfer an der Universität Bielefeld GmbH

Universitätsstr. 25 University of Bielefeld33615 Bielefeld+49 521 100-775+49 521 [email protected]

30


Name


Fon

E-Mail Internet


Name


FonFax

E-Mail Internet


Protagen Protein Services (PPS) is a leading contract research organization with an large international customer base in the field of Protein Analytics of biotherapeutics. With more than 17 years of experience in busi-ness, PPS is able to offer a comprehensive, GMP compliant spectrum of state of the art analytical methods, ensure the highest quality for the identification and structural

characterization incl. modification of new biological entities as well as biosimilar prod-ucts. Comprehensive proteome studies and differential protein display techniques are offered in addition for example to support up and downstream process optimization of biotherapeutic production. PPS combines unique expertise in e.g. bioinformatics for protein mass spectrometry with a long track record in protein chemistry and protein analytics. PPS provides you with the full range of services, from drug discovery and development to release testing and regula-tory compliance under ICH Q6B.

Presently the following In Stock products are available: various reporter-gene plas-mids and minicircles, pDG plasmids for the AAV virus production and pEPI /pEpito plasmids with S/MAR elements.

PlasmidFactory’s research and devel-opment as well as its complete service branches are based in Germany. With vari-ous research projects and co-operations, PlasmidFactory is the driving force in the development of gene vectors.

PlasmidFactory is the leading contract manufacturer for plasmid and minicircle DNA. The so-called ‘In Stock products’ are complementing the product portfolio: these plasmids are always in stock and are usually shipped within 48 hours of order.

PlasmidFactory GmbH & Co. KG

Meisenstr. 9633607 Bielefeld

+49 521 2997-350 +49 521 2997-355 www.plasmidfactory.com [email protected]

16 2000

PAIA Biotech GmbH offers assays for the rapid quantification of antibodies and proteins based on its proprietary assay technology. It features bead-based im-munoassays with fluorescence detection in specially designed 384-well microplates which drastically simplify the workflow. The

assays are amenable to automation and run on standard plate readers or fluorescence microscopes. PAIA Biotech focuses on products for screening applications with limited sample volume and high throughput requirements, e.g. in early cell line develop-ment.

In addition to off-the-shelf products for IgG and IgG fragments PAIA Biotech GmbH also offers custom assay development. PAIA Biotech GmbH was founded in 2014 and is based at the RTZ in Cologne.

PAIA Biotech GmbH

Gottfried Hagen Str. 60-6251105 Köln

+49 221 16862380

[email protected] 42014

Name


FonFax

E-Mail

Internet


Protagen Protein Services GmbH

Otto-Hahn-Straße 1544227 Dortmund+49 231 9742-6100+49 231 9742-6149contact@ProtagenProteinServices.comwww.ProtagenProteinServices.com521997

31


Name


FonFax

E-Mail Internet

Founded (year)

Name


FonFax

E-Mail

Internet

Founded (year)

Name


FonFax

E-Mail Internet


PS Biotech is German innovative developer and producer of polymer-releases systems for biotechnological application. Based in Aachen, founded in May 2013, the com-pany is best-known for their proprietary Feed Plate® high throughput screening technology enabling fast individualized optimization and scale-up of industrial bio production processes. In Feed Plate® nu-trients are released from a special polymer

matrix, immobilized at the bottom of a mi-croplate. Feed Plate® enables the genera-tion of precise, process near conclusions during high throughput screening, result-ing in an optimized scale-up procedure. Synchronization of physiological condi-tions in screening and production leads to reliable results in unknown quality and thus immensely increases the efficiency within the scope of screening and application in production..

PS Biotech GmbH

Kackertstraße 4

52072 Aachen

+49 241 8946441-0+49 241 [email protected]

2013

The Soluventis-platform is based on the most powerful drug delivery system, an entirely new type of Nanocarrier charac-terized by incomparable high efficacy and a very good safety profile. The Soluventis Nanocarrier shields the transported siRNA, microRNA or peptides from blood and im-

mune system contact, and reaches reliable target organs including poorly vascularized tumor tissue. The targeting of metastases is excellent. The frozen Nanocarrier has a long shelf life in ampoules whereas in the organism it is completely eliminated within two days.

Soluventis has a portfolio of oncologic siRNAs which significantly improve tumor reduction and elimination of metastases in xenograft models. In combination with the novel drug delivery system we offer a faster and more effective development of clinical candidates for pharmaceutical companies.

Soluventis GmbH

Im Lottental 3644801 Bochum +49 234 32-29125+49 234 [email protected]

2009

Squarix GmbH is a privately-held primary manufacturer of high purity Discovery Chemicals and Immunoreagents. Since 1992, Squarix produces a broad product line of compounds that include innovative building blocks, reactive intermediates, natural products and derivatives, screening

compounds for drug discovery industry and reagents for life science applications com-prising antibodies, metabolic intermediates, fluorescent dyes & probes and different af-finity matrices for proteins and cells.

Moreover, Squarix is a custom producer of polyclonal and monoclonal antibodies for biomedical research and offers all type of immunoanalytical services in the field of antibody technology.

Squarix GmbH biotechnology

Elbestr. 1045768 Marl

+49 2365 915-278 +49 2365 915-254 [email protected]

81992

32


Name


FonFax

E-Mail Internet


Taconic Biosciences GmbH

Neurather Ring 151063 Köln

+49 221 96453-0+49 221 [email protected] www.taconic.com

801952

Taconic Biosciences is a global provider of genetically engineered rodent models and services. Founded in 1952, Taconic helps the biotechnology and pharmaceutical communities acquire, custom generate, breed, precondition, test, and distribute highly relevant research models world-wide. Specialists in Precision Research Models and GEMS Design & Management, Taconic operates three service laborato-

ries and six breeding facilities in the U.S. and Europe and maintains distributor relationships in Asia.

vivo Science is a privately held CRO for pre-clinical studies focussing on the immune system. For years now, all regulatory agen-cies such as FDA or EMA very much enforce the testing of immunotoxicity (ICH-S8) and immunogenicity (ICH-S6) of new drug can-didates, especially if derived from biotech-

nology. In addition, vivo Science can also include immunological tests into standard toxicity studies for a medicinal product. vivo Science will provide GLP and GMP compli-ant, validated study protocols and will assist you in setting up a customized test program for your special requirements.

Name


FonFax

E-Mail Internet


Sysmex Partec is the newly formed collabo-ration between Partec, a worldwide leading pioneer, developer and manufacturer of flow cytometry systems and Sysmex Corpora-tion, a leading international supplier of in vitro diagnostic products.

Sysmex Partec products are used in a wide range of applications in healthcare,

immunology, cell biology, microbiology, biotechnology, agrosciences, plant breed-ing, aquaculture and in pharmaceutical, food and beverage industries.

The company is recognised as one of, if not the foremost global force in essential healthcare by widely providing robust and affordable hi-tech diagnostic solutions to resource poor markets.

With its new partnership, Sysmex Partec is now available in more than 150 countries worldwide.

Sysmex Partec GmbH – Branch Office Münster(Headquarter: Am Flugplatz 13, 02828 Görlitz)Otto-Hahn-Str. 3248161 Münster+49 3581 8746-0+49 3581 [email protected]

195 worldwide1967

Name


FonFax

E-Mail Internet


vivo Science GmbH

Fabrikstr. 348599 Gronau

+49 2562 8170-0 +49 2562 8170-19 [email protected]

202001

33


Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Xell AG

Alte Verler Str. 133689 Bielefeld+49 521 96989-200+49 521 [email protected]

212009 as TeutoCell AG, renamed in 2014

Xell is an experienced partner for companies in the biotech and pharmaceutical industry providing them with highly-efficient solu-tions in cell culture technology. With years of industry experience, we bring our extensive expertise in high performance media and feed development, and apply our powerful

analytical tools for in-depth characteriza-tion of biological systems and pharmaceuti-cal proteins, guaranteeing optimal solutions for our customers’ bioprocesses.

Based on our proprietary technology, Xell has developed a wide range of customized as well as commercial high-performance culture media, supplements and feeds for specialized production cell lines includ-ing CHO, hybridoma and HEK. Chemically defined and free of animal components, our products meet or exceed all necessary quality standards required for GMP manu-facturing processes.

XanTec bioanalytics GmbH

Merowingerplatz 1a40225 Düsseldorf

+49 211 9936-4744 +49 211 9936-4746 [email protected]

101997

XanTec bioanalytics specializes in biosen-sors and bio-nanocoatings. The company’s core competence are bioinert and bioac-tive nanocoatings for biomedical and bio-analytical applications. Products are SPR biosensor systems, SPR or other biosensor chips and coated slides for protein and DNA microarrays.

34

BIO.NRW

Health and Medicine (including Animal Health)

BIO.NRW health and medicine

35

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet

Founded (year)

AiCuris GmbH & Co KG, is a privately held company located in Wuppertal, Germany. AiCuris is devoted to research and clinical development of novel, resistancebreaking drugs for the treatment of HCMV, Herpes, Hepatitis B and HIV as well as resistant Gram positive and Gram negative bacterial infections in hospitals.

Affectis is a pharmaceutical company developing novel proprietary drugs for the treatment of neurodegenerative and neuroinflammatory diseases based on pioneering findings in the field of P2X7 receptors. Affectis will partner or license

Furthermore, the portfolio comprises two immune modulators, one for auto-immune diseases, the other for hepatitis B/C and fibrosis.

For its innovative portfolio of HCMV drugs AiCuris entered into a worldwide license agreement with Merck (known as MSD outside the US) in October 2012.

its programs at late discovery/early de-velopment stage. The company is located in Dortmund, Germany, and is looking for academic and industrial collaborations for testing its frontrunner compound.

A2M Pharma is a spin-off from Schwarz Pharma with the aim of developing the most promising projects of Schwarz Pharma’s former R&D pipeline that was abandoned for strategic reasons following its merger with UCB.

This portfolio includes projects in neu-rology and pain. A2M Pharma develops these projects until clinical proof of con-

cept which will then be out-licensed or partnered. The current lead projects focus on the treatment of Parkinson’s disease and are supported by the Michael J Fox Foundation. A small molecular modulator of lipid rafts is in preclinical development as an α-synuclein aggregation inhibitor for disease modifying treatment of Par-kinson’s Disease and potential for other protein aggregation disorders. The second lead project focusses on the treatment of dyskinesias and involves a NCE for transdermal delivery.

AiCuris GmbH & Co. KG

Friedrich-Ebert-Str. 47542117 Wuppertal

+49 202 31763-0 +49 202 31763-1177 [email protected]

60 2006

Affectis Pharmaceuticals AG

Otto-Hahn-Str. 1544227 Dortmund

+49 231 97427000+49 231 [email protected]

2004

A2M Pharma GmbH

Alfred-Nobel-Str.1040789 Monheim

+49 2173 16505-78 +49 2173 16505-81 [email protected]

32009

http://www.a2m-pharma.com

BIO.NRWhealth and medicine

36

Name

Address

Postal Code/City

FonFax

E-Mail Internet


Algiax Pharmaceuticals GmbH is an biotech-nology company that was established in April 2011. It is dedicated to the discovery and development of innovative products in the field of nervous system disease with a strong focus on neuropathic pain. The company’s lead compound AP-325 is currently in clinical development. The comprehensive Phase I program is ongoing (>100 male and female

subjects exposed to AP-325) and shows a good safety and tolerability profile in healthy volunteers after single and multiple dosing. The human PK profile of AP-325 is compatible with once-a-day administration and fast onset of action. A broad patent portfolio covering major commercial markets is solely owned by Algiax. The primary indication is neuropathic pain, the secondary indication is spinal cord injury for which Algiax has an orphan drug des-ignation. Altogether, Algiax is well positioned to take advantage of the market opportunity not only in the field of neuropathic pain but also in other unmet nervous system disorders.

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


arrows biomedical Deutschland carries out contract research and clinical routine analyses, and also pursues its own R&D projects. The firm’s areas of focus are primarily in the fields of molecular oncol-ogy and neurodegenerative disease. Its portfolio of molecular analytics includes RNA/DNA. services like RNA/DNA isolation,

microarrays(GenExpression, Array-CGH, ChIP on chip, DNA-Methylation-Microar-rays), PCR (RT-qPCR) and bioinformatics. In the area of medical diagnostics, the portfolio includes routine analysis (testing for all clini-cal relevant biomarkers and the complete range of blood analysis), flow cytometry (NAVIOS), HPLC analysis, diagnostic micro-arrays, detection of freely circulating tumor cells, and chemosensitive analysis. Further-more, FISH analysis, general microscopy with the Zeiss axio imager M 2 in combina-tion with the MetaSystemsSoftware and Pyro- and Sanger sequencing.

Axiogenesis focuses on pharmaceutical biotechnology, specifically in the reasarch, production and sale of human iPS derived cells and assays. Beginning with mouse embryonic stem cell (mESC)-derived cardiomyocytes in 2001, the company expanded its product range to human in-duced pluripotent stem cell (iPSC)-derived cardiomyocytes and neuronal cells.

Axiogenesis has 13 years of experience in assay development, either in-house or in cooperation with platform providers, includ-ing assays for cardiac drug development and addressing cardiotoxicity.

Axiogenesis’ assays are based on pure, in vitro differentiated, stem cell derived cell types. Axiogenesis’ CRO services include cardiac toxicity, embryo-toxicity and human cardiac electrophysiology (MEA). These innovative and proprietary assays acceler-ate and improve drug candidate selection, lower costs and thus increase overall drug development efficiency.

GENESISUse our discoveries to advance yours

arrows biomedical Deutschland GmbH im CeNTech der WWU Münster

Heisenbergstraße 11 48149 Münster+49 251 534064-00+49 251 [email protected]

102005

Axiogenesis AG

Nattermannallee 1Gebäude S2050829 Köln

+49 221 998818-0 +49 221 998818-10 [email protected]

23 2001

Algiax Pharmaceuticals GmbH

Max-Planck-Str. 15a40699 Erkrath

+49 211 617851-0+49 211 [email protected] www.algiax.com

62011


37

Name

AddressPostal Code/City

Fon

Internet

Employees

Name

AddressPostal Code/City

FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of around EUR 20.0 billion (2014), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The com-pany combines the global activities of the

Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 60,700 employees (Dec 31, 2014) and is represented in more than 100 countries. More information is available at www.healthcare.bayer.com.

Biocheck introduced Polycheck® Platform Technology as a tool for medical differen-tial diagnosis. The multiparameter test device enables a serological quantitative allergy screening on the basis of solid phase Immuno-Assay-Technology using monoclonal antibody detection; color-coded devices are presenting different allergen panels. For autoimmune diagnosis a quantitative screening for disease pat-

terns is new family member of Polycheck®. Quantitative evaluation is performed by picture scanning and calculation by Bio-check Imaging Software.

The assay prodedure can be worked out manually or fully automated including matching with central Laboratory Informa-tion Systems (LIS).

Bayer HealthCare AG

Kaiser-Wilhelm-Allee51368 Leverkusen

+49 214-30-1

www.healthcare.bayer.com

60,700

BioCheck GmbH

Vorbergweg 4148159 Münster

+49 251 2150-868 +49 251 2150-870 [email protected]

14 1999

Baliopharm is a pharmaceutical company firstly offering services for the preclinical and clinical development of biopharma-ceutical compounds and secondly dedi-cated to the development of new innovative biopharmaceutical compounds for the treatment of inflammatory diseases such as rheumatoid arthritis, Morbus Crohn and multiple sclerosis. Our lead product

ATROSAB, a humanized anti-TNF-receptor antibody, currently in phase I clinical studies, has been proven in head to head comparative, preclinical studies to be more safe and more efficacious as state of the art marketed products.

In addition, Baliopharm s service arm is GLP/GMP certified for analytics needed in preclinical and clinical studies We perform all kind of serum analytics needed for the development of biopharmaceutical com-pounds. We also offer a wide set of cell based potency assays for new biological as well as for biosimilar products.

Baliopharm GmbH

Karl-Heinz-Beckurts-Str. 1352428 Jülich

+49 2461 6210-855 +49 2461 [email protected] 202011


38

Biofrontera AG is a biopharmaceutical company specializing on the development of drugs and medicinal cosmetics for the treatment of skin diseases and the regen-erative care of damaged skin. Headquar-tered in Leverkusen, Germany, Biofrontera is a publicly listed on the Frankfurt Stock Exchange (Prime Standard) and London Stock Exchange (AIM) – B8F / ISIN: DE

0006046113. In February 2012 Biofrontera launched its prescription drug Ameluz® for the treatment of actinic keratosis on the German market. In other European coun-tries Ameluz® is marketed through local partners. Ameluz® is applied in Photody-namic Therapy requiring a powerful source of red light. For this purpose Biofrontera has developed the BF-RhodoLED® lamp, which was CE marked in November 2012. As cosmeceutical products Biofrontera markets Belixos® crème and the Belixos product family for the regenerative care of reddened, inflamed und sun-damaged skin.

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


CAP-CMV GmbH is a venture capital backed vaccine development company founded in 2013 and based in Cologne. CAP-CMV develops the most promising vaccine to prevent human cytomegalovi-rus (HCMV) infection and related diseases. HCMV infection is the leading cause for mental retardation in newborns and caus-es serious clinical manifestations in solid

organ and bone marrow transplantations. There is no vaccine to date, medical need is high and market expectations are in the blockbuster range.

CAP-CMV uses non-infectious HCMV dense bodies (DB) as immunogen, shown to create long lasting humoral and cellular immune responses in animals. DB carry the most complete set of antigens to gen-erate efficient immune responses but no capsid and DNA. DB can be produced in human CAP cells at industrial scale.

CAP-CMV

Gottfried-Hagen-Str. 6251105 Köln

+49 221 9957 2601 +49 221 4602 [email protected]

< 102013

Biofrontera AG

Hemmelrather Weg 20151377 Leverkusen

+49 214 87632-22 +49 214 87632-90 [email protected]

46 1997

Carpegen is a provider of high quality mo-lecular diagnostics. The company focuses on developing real-time PCR assays and point-of-care diagnostic (POC) systems for the diagnosis of specific infections and the detection of genetic biomarkers. Carpegen has developed Carpegen® Perio Diagnostics, a powerful real-time PCR

based system that sets new standards in microbiological periodontal diagnostics. This widely recognized test is extensively used by European dentists to optimize the treatment of periodontal diseases. A main objective of Carpegen’s research program is to develop and out-license POC systems for diverse applications in medical and non-medical markets. A project related to the development of food POC analytics is currently being pursued with financial support of the German Federal Ministry for Economic Affairs and Energy.

Carpegen GmbH

Mendelstr. 1148149 Münster

+49 251 980-2320 +49 251 980-2321 [email protected]

102001


39

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


CEVEC is a global solution provider for the production of biopharmaceuticals using a unique human cell expression system.

CEVEC’s CAP-Go expression platform comprises a portfolio of glyco-optimised human suspension cell lines for tailor-made glycosylation of recombinant proteins. The cells are highly efficient for the production of a broad range of difficult to express gly-

coproteins and provide authentic human post-translational modifications. CAP-Go has proven to enhance the activity, stabil-ity and serum half-life of several candidate proteins.

To address the current need for a fully scalable production system for gene ther-apy vectors, CEVEC provides the CAP-GT expression platform. CAP-GT cells grow to high cell densities, show a broad viral propagation spectrum including LV, AAV, AV and allow for easier scale-up and re-duced production costs when compared to adherent cell culture systems.

CEVEC Pharmaceuticals GmbH


+49 221 46020-800 +49 221 46020-801 [email protected]

202003

CellAct Pharma GmbH is a venture backed biotech company focused on the develop-ment of innovative therapeutics for the treatment of cancers with high unmet need. CellAct’s drug candidates target and modulate human molecules which have specific functions in tumor growth.

The small molecule compound, CAP7.1 which targets Topoisomerase, is currently in clinical Phase II study for the treatment of therapy refractory cancers of the biliary tract as well as small-cell and non-small cell-lung cancers. Orphan Medicinal Products of the European Medicines Agency (EMA) has recently granted orphan drug designa-tion to CAP7.1, for the treatment of biliary tract cancers which is given to products for the treatment of rare diseases that are life-threatening or very serious.

CellAct Pharma GmbH


+49 231 9742-6350 +49 231 9742-6355 [email protected]

42007

Cilian AG is a biotechnology company de-veloping and marketing a novel expression system. The company uses a species of Ciliates, a eukaryotic single-cell organism, for the production of vaccines, monoclonal antibodys and therapeutic enzymes.

Cilian AG

Johann-Krane-Weg 4248149 Münster

+49 251 6203-114 +49 251 6203-116 [email protected] 142001


40

Name


FonFax

E-Mail


Name


FonFax

E-Mail Internet


CIRES is experienced in all kinds of cell culture techniques, ranging from genera-tion of hybridomas, culture of mammalian cells in general and the culture of lines of transgenic cells.

Colbourne Pharmaceuticals develops and produces drugs for the treatment of inborn errors in metabolism and offers diagnostic services for molybdenum cofactor defi-ciency and sulphite oxidase deficiency. Colbourne Pharmaceuticals provides ser-vices to Alexion Pharmaceuticals Inc. in the development of cPMP for the treatment of molybdenum cofactor type A deficiency.

CIRES Cell & Immune Research Services

Emil-Figge-Str. 76a44227 Dortmund

+49 231 974-2880+49 231 [email protected]

32001

ColbournePharmaceuticals GmbH

Viktoriaweg 7 53859 Niederkassel

+49 2208 770505+49 221 [email protected]

62008

Name


Fon E-Mail

Internet


The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to

treat unmet medical needs and bring value-adding products to markets. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.

Altogether, the Grünenthal Group is present in 32 countries with affiliates in Europe, Australia, Latin America and the US. Grünenthal products are sold in more than 155 countries and approx. 5,200 employees are working for the Grünenthal Group world-wide. In 2014, Grünenthal achieved revenues of € 1.154 bn.

Grünenthal GmbH

Zieglerstr. 652099 Aachen

+49 241 569-0 [email protected]

5,2001946


41

Name


FonFax

E-Mail Internet


First diagnostic test to detect perinatal asphyxia (PA, oxygen deficit during birth) and related braindamage.

PA is very prevalent in childbirth world-wide with 0.5-4% of births affected. Typi-cal outcome brain damage results in e.g. cerebral palsy/spasticism, blindness etc. Therapy is available and reimbursed since 2010, but needs to be started within 6 h

Janssen-Cilag is a research-based pharma-ceutical company that develops and mar-kets pharmaceutical products and services. The Janssen Pharmaceutical Companies of Johnson & Johnson with worldwide 40,000 employees develop innovative medicines for the treatment of severe chronic conditions and evaluates programmes that improve

after delivery. No suitable diagnostic ex-ists today. Thus, ca. half of cases are not treated. Still, up to 15 unnecessary treat-ments are applied to cure one patient.

InfanDx develops the first test to be applied immediately after birth. The im-munology like format uses a small blood sample only. Technology origin is metabo-lomics research.

InfanDx seeks partnerships as.– pharma-partnering, („companion diagnostic“, therapy monitoring)– manufacturer of point-of-care device– marketing co-operations

therapies beyond the mere administration of drugs. Janssen is dedicated to address-ing and solving the most important unmet medical needs of our time, including on-cology, immunology, neuroscience and infectious diseases. Driven by our commit-ment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and trans-parency. More information can be found at www.janssen-emea.com and www.janssen-deutschland.de

InfanDx AG

Balthasarstr. 1850670 Köln

+49 221 30089783+49 221 [email protected]

<102010

Name


Fon Fax

Internet

Employees

Founded (year)

Janssen-Cilag GmbH

Johnson & Johnson Platz 141470 Neuss

+49 2137 9550+49 2137 955599

www.janssen-deutschland.de

800 (Germany),40,000 (worldwide)1959

Name


FonFax

E-Mail Internet


Bridging the gap between academic dis-coveries and pharmaceutical development.

Active in the field of pharmaceutical research, LDC transforms promising early-stage projects into marketable assets providing industry with high-quality leads with proof-of-concept in animals. LDC conducts small molecule drug discovery

projects in close collaboration with aca-demic researchers from its broad network including top institutes from the Max Planck Society, Helmholtz Association and numer-ous universities. The LDC team consists of experts with solid industry experience in project management as well as Automation & Screening, Cellular Biology, Pharmacol-ogy and Medicinal Chemistry.

LDC has formed alliances with AstraZen-eca, Bayer, Merck Serono, Daiichi Sankyo, Qurient, Johnson & Johnson as well as leading academic drug discovery centers around the globe.

Lead Discovery Center GmbH


+49 231 9742-7000+49 231 [email protected]

602008


42

Name


FonFax

E-Mail Internet


LIFE&BRAIN is a development-stage biomedical enterprise serving as com-mercial hub of the University of Bonn Medical Center. As a centre of innovation, LIFE&BRAIN features a unique structure in Germany’s translational research land-scape. Spread across four R&D platforms LIFE&BRAIN employees and academic staff of the University of Bonn work to-

gether under one roof to develop novel strategies for the diagnosis and therapy of nervous system disorders.

LIFE&BRAIN’s R&D platforms combine expertise in stem cell technology, genetics, transgenics and neurocognition. Products and services include genome and gene ex-pression analysis, human stem cell-based models of neurological disease and their use in compound development as well as brain imaging-based applications in neuroeconomics.

Life & Brain GmbH

Sigmund-Freud-Str. 2553127 Bonn

+49 228 6885-100 +49 228 6885-101 [email protected]

40 2002

Matricel GmbH develops and produces innovative medical class III collagen im-plants and biomatrices for applications in medicine and biotechnology. Matricel proprietary technologies are the key to successfully produce biocompatible and biodegradable matrices in a wide range of modifications suitable for the cultivation with human cells in tissue engineering and

regenerative medicine. The products serve different medical fields like ACI-Maix and Cartimaix for tissue engineering of articu-lar cartilage and other orthopedic applica-tions and Remaix as a dental membrane for guided bone regeneration. Matricel s product Optimaix is dedicated for research in 3D cell culture. Matricel has a promising product pipeline in further medical fields like dermal and nerve regeneration with customized scaffolds.

Name


Fon E-Mail

Internet


Matricel GmbH

Kaiserstr. 10052134 Herzogenrath +49 2407 [email protected]

282001

Name


Fon E-Mail

Internet


Based in Germany and the USA, Medical Adhesive Revolution develops one-of-its-kind polyurethane-based glues. The company was founded in 2013 in Aachen, Germany and is based on a technology which has been developed since 2007. The technology is unique, as it combines ease of use, strength, flexibility and biodegrada-bility. Two products are currently under de-

velopment: The first is intended for dermal use, to close topical wounds faster, more accurately and with fewer complications. The second is designed for use inside the body: either as an adhesive, to seal areas of leakage or re-attach tissue, or as a hemo-stat, to stop even arterial bleeding. Unlike other technologies, the product can be used instantaneously and stops bleeding within seconds. This enables it to save lives in emergency situations and significantly reduce hospitals costs.

Medical Adhesive Revolution GmbH

Pauwelsstraße 17 52074 Aachen

+49 241 [email protected]

72013


43

Name


Fon

E-Mail Internet

Founded (year)

Name


FonFax

E-Mail

Internet


MetaVì Labs provides drug discovery services for cell migration inhibitors to biotech and pharmaceutical companies and research labs worldwide.

MetaVì Labs’ process is based on a 3-D collagen matrix system that recapitulates the tumor environment to measure live tumor cell migration. This is the only cell

migration method that has been clinically validated for in vitro screening of drugs for antimetastatic effects. The company’s patent pending microscopy system au-tomatically tracks thousands of cells as individuals as they migrate freely in 3-D collagen.

MetaVì Labs GmbH

Alfred-Herrhausen-Str. 45 58455 Witten

+49 171 8624163

[email protected]

2012

miacom was founded with the vision to excel in the speed of identification and characterization of microorganisms. Since it’s founding the company has completed the development of a novel platform tech-nology for routine molecular testing based on enhanced “beacon-based fluorescence in-situ hybridization (bbFISH). miacom’s tests allow the simultaneous identifica-tion of up to 14 pathogens on a single

microscope slide in 30min. Hands-on time of 10min and the accuracy of a molecular diagnostic method enable STAT as well as routine applications. Tests for bacteremia and pneumonia are commercially available – additional tests will be launched in the future. In addition, miacom offers 15min screening tests for Staph. aureus versus coagulase negative Staphylococci.

miacom diagnostics GmbH

Merowingerplatz 1a 40225 Düsseldorf

+49 211 3015-5795+49 211 2989-143info@miacom-diagnostics.comwww.miacom-diagnostics.com62006

Name


FonFax

E-Mail Internet


MLM Medical Labs is a CAP- and DIN EN ISO 15189-accredited, GLP-certified and CLIA-registered central and specialty lab dedicated exclusively to clinical trials phase I to IV. MLM offers the entire portfolio of service ele-ments to support clinical trials:– Development and validation of special analytical methods– Global supply of study-specific sampling kits– World-wide sample logistics

– Clinical chemistry, hematology, serology and urinalysis– Biomarker assays including multiplex panels– Long term cryo-storage of samples– Web Access - mlm online®

MLM’s clients are CROs, biotech and global pharmaceutical companies based in Europe, Asia and USA. MLM’s services are offered 365 days a year. We create a reliable partner-ship with our clients and our core values are:– Scientific Excellence– Customized Solutions– Personal Accountability

MLM Medical Labs GmbH

Dohrweg 6341066 Mönchengladbach

+49 2161 4642102+49 2161 [email protected]

341993


44

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Morphoplant GmbH is a bio-/ medtec company headquartered at the BioMedizin-Zentrum in Bochum and focused on the inte-gration of biotech functionalities into medical devices. Laboratories equipped with state-of-the-art technology for recombinant protein

NEO New Oncology AG is a molecular di-agnostics company dedicated to the fast, reliable identification and interpretation of all therapy-relevant genomic changes in cancer patient samples.

The proprietary technology platform “NEO” delivers clinically meaningful results from just one small sample, either a tissue paraffin block or blood. Based on advanced

NEUWAY Pharma GmbH is focused on the development of a delivery system for CNS drugs. This system is based on a protein that naturally forms capsules. These capsules may be used as a platform to transport molecules - ranging from small chemicals

production, protein chemistry, molecular and cell biology, isotope protein labeling/ monitoring and optical biosensor technol-ogy are available to our experienced and multidisciplinary R&D team. Morphoplant’s proprietary technologies provide our cus-tomers with ultrahydrophilic and osteophilic long-term storable metal implant surfaces and solutions for biocoating of a variety of implant materials with recombinant growth factors (bone/ vascular). Our outstanding expertise in surface functionalization, protein adsorption, kinetics monitoring and animal testing is also available for contract research.

diagnostics combined with oncological expertise, “NEO” identifies all available treat-ment options ranging from standard thera-pies to clinical studies, enabling clinicians to fully understand individual cancer profiles and to make informed treatment decisions. NEO New Oncology AG is privately funded and maintains partnerships with clinics as well as major pharmaceutical companies.

to large nucleic acid strands – across the blood-brain barrier.

NEUWAY plans to partner its technology with drug developers when large indications, like Alzheimer’s disease, are addressed. However, for the treatment of rare diseases, own clinical development programs may be performed.

The company is backed with venture capital from renowned investors and a strong board.

Morphoplant GmbH

Universitätsstr. 13644799 Bochum

+49 234 7772870+49 234 [email protected]

142002

NEO New Oncology AG


+49 221 888 238-0+49 221 888 [email protected]

202012

NEUWAY Pharma GmbH

Ludwig-Erhard-Allee 253175 Bonn

+49 228 522798-0+49 228 [email protected]

102014


45

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Nexigen GmbH leverages its extensive R&D experience in peptide therapeu-tics for the efficient discovery and ra-tional development of peptide medicines (“NexiTides”) with qualified cellular mechanisms of action.

Nexigen’s technologies give access to high value drug targets which pose signifi-

cant challenges to conventional discovery approaches. Targets include aberrantly activated intracellular disease pathways in so-called cancer stem cells, for which currently no treatment alternatives exist, but which are main drivers of tumor recur-rence and spread.

Nexigen was founded in 2007 and is headquartered at the BioCampus Cologne, Germany.

PAION AG is a publicly-listed Specialty Phar-ma Company headquartered in Aachen, Germany, with further sites in Cambridge, UK, and New Jersey, U.S. PAION has a track record of developing hospital-based treat-ments for which there is substantial unmet medical need.

PAION is committed to delivering medical innovations in procedural sedation, anes-thesia and intensive care for patients and physicians; building its business around its lead compound Remimazolam and extend-ing its business with a focus on anesthesia and critical care products.

PAION is listed at the Frankfurt Stock Ex-change (Prime Standard Regulated Market, Stock Symbol PA8, ISIN DE000A0B65S3).

Since over 60 years, Pharma Waldhof GmbH, located in Düsseldorf/Germany, is active in the unique world of Nucleic Acid Biochemistry. The last milestones in our long company history were in 2014 the award of the label “Innovative through Research” by the “Stifterverband für die deutsche Wissenschaft” and in 2015 the acknowledgement by the “Deutscher Bil-

dungspreis” as an “Excellence company for Training and Talent Management”.

Development of new products using cut-ting-edge technology enables us to apply our high standards and quality values into inno-vative, powerful and well-accepted products designed for existing and new markets. Our success is based on our highly skilled people and pursuit for delivering quality value added products serving the worldwide market in various segments like Pharma APIs and Intermediates; Cosmetics; Nutrition and Diagnostics. Pharma Waldhof belongs to the multi-national Aceto Group/USA.

Pharma Waldhof GmbH

Hansaallee 15940549 Düsseldorf

+49 211 52602-0+49 211 [email protected]

131974

Paion AG

Martinstr. 10-1252062 Aachen

+49 241 4453-152+49 241 4453-523 [email protected]

272000

Nexigen GmbH


+49 221 337772-00+49 221 337772-29 [email protected]

232007


46

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Name


FonE-Mail

Internet


Protectimmun GmbH is a biopharma-ceutical R&D company focussed on new approaches in the prevention and therapy of allergic and chronic inflammatory dis-eases. Our innovative concept for product development is based on the identifica-

tion of natural substances and bacteria with immunomodulatory properties from particular farm environments which are selectively transferred into pharmaceuti-cal applications. Promising candidates which were successfully tested in proof-of-concept animal models of asthma are currently in mid- to late-stage preclinical development.

Protectimmun GmbH

Ückendorfer Str. 237e45886 Gelsenkirchen

+49 209 389 665 [email protected] < 102007

Diagnostics Differentiated - Protagen AG improves Personalized Patient Care

At Protagen, we are dedicated to the de-velopment of novel diagnostic tests (Dx & CDx) for autoimmune diseases. Utilizing a personalized medicine approach, our multi-marker assay technology SeroTag® enables differential diagnosis, patient stratification and response prediction for

RA, SLE, SSc and others. This is evidenced by our broad development portfolio of novel Dx, the first of which was launched as a research test in 2014.

The identification of patient subgroups has become essential for developing novel medicines. Protagen is adressing this problem with NavigAID SLE to define homogeneous patient subgroups in SLE, enabling successful drug development.

Protagen Diagnostics: Selecting the right drug for the right patient!

Protagen AG


+49 231 9742-6300 +49 231 9742-6301 [email protected]

371997

Pharmedartis (PMA) develops next genera-tion targeted therapies. This platform tech-nology of Human Cytolytic Fusion Proteins (HCFP) has several advantages over well-received ADCs. A binder is recombinantly fused to a payload. This can be proteases,

RNases or kinases. Since the binder can be almost anything making it truly scalable. Human payloads should have much less side-effects. We look for partner interested in out-licensing opportunities for these first-in-class products. We develop CFPs to treat cancer, inflammation, auto-immune and skin diseases. 6 products are in preclini-cal testing. CFPs for clinical testing can be produced in Aachen in proprietary system at a state-of-the-art GMP facility of Fraunhofer Society, of which PMA is a spin-off. As a one-stop-shop we provide full service from gene to biopharmaceutical product.

Pharmedartis GmbH

Forckenbeckstr. 652074 Aachen

+49 241 6085132-60 +49 241 6085132-66 [email protected]

52007


47

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


QIAGEN is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecu-lar insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. As-say technologies make these biomolecules

visible and ready for analysis. Bioinformat-ics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 custom-ers around the world in Molecular Diagnos-tics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and bio-technology companies) and Academia (life sciences research). Further information can be found at http://www.qiagen.com

Rhein Biotech GmbH, the European sub-sidiary of Dynavax Technologies, USA, has over 25 years of experience in biotechnol-ogy and is dedicated to the manufacture of biopharmaceuticals. We have successfully developed production technologies for a wide span of products, including a recom-

Rigontec GmbH is a privately held bio-pharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases.

Rigontec was launched in January 2014 as a spin out of the Institute for Clinical Chemistry and Clinical Pharmacology at the University Hospital of the University of Bonn, Germany.

binant Hepatitis B vaccine which is part of national and supranational vaccination programs worldwide. Our technology for Hepatitis B production is also the basis for the investigational adult Hepatitis B vaccine, HEPLISAV™, a lead product candidate of Dynavax Technologies Corporation.

The company has raised €14.25 million in its recent Series A financing round and is operating at two locations in Bonn and in Munich, both in Germany.

Rigontec is supported by a consortium of experienced Life Science investors in-cluding Wellington Partners, Boehringer Ingelheim Venture Fund, NRW.BANK, High-Tech Gründerfonds (HTGF), Forbion Capital Partners, Sunstone Capital and MP Healthcare Venture Management.

Rigontec considers itself as a leading company in the field of RIG-I technology.

Rhein Biotech GmbH (Dynavax Europe)

Eichsfelder Str. 1140595 Düsseldorf

+49 211 75845-0 +49 211 75845-130 [email protected]

70 1985

Rigontec GmbH

Sigmund-Freud-Straße 2553127 Bonn

+49 228 763701-10+49 228 [email protected] www.rigontec.com

82014

QIAGEN GmbH

Qiagen Str. 140724 Hilden

+49 2103 29-0 +49 2103 29-22000 [email protected]

>4,300 worldwide1984


48

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


SanguiBioTech GmbH engages research and development of pharmaceutical, medical and cosmetic products. Many of their tech-nologies are patented and unique.

Soft Intelligent Therapeutics (SIT) is a biotech company focused on personalized cancer treatments combining maximum efficacy with minimum side effectsThe first product candidate of its targeted gene delivery platform is designed to separately and selectively deliver via two different

Sividon Diagnostics is a spin-off from Siemens Healthcare Diagnostics´ former research group in Köln. Its management team represents decades of professional experience in molecular diagnostics. Sividon develops and markets innovative products to improve the individualized selection of therapies in oncology. The company currently focusses on breast

cancer, the first product being EndoPre-dict®, a breast cancer test identifying those patients who can be cured with an antihormonal treatment and therefore be spared an aggressive chemotherapy. It is worldwide the first RNA-based diagnostic test for breast cancer that can be carried out in any well-equipped molecular pathol-ogy laboratory.

Also, Sividon is a member of the Europe-an study group “RESPONSIFY – Genome-based biomarkers leading to validated molecular diagnostic tests for response prediction in breast cancer”.

Sividon Diagnostics GmbH


+49 221 669561-00+49 221 [email protected]

202010

SanguiBioTech GmbH

Alfred-Herrhausen-Str. 44 58455 Witten

+49 2302 915200+49 2302 [email protected]

61995

SIT - Soft Intelligent Therapeutics Biotech GmbHOtto-Hahn-Str. 1544227 Dortmund

+49 231 97427252+49 231 [email protected]

62010

binding sites two inactive compounds to cancer cells, where they combine to an ac-tive product initiating apoptotic processes.In parallel SIT develops novel intelligent and highly specific liposomal payloads on DNA basis for different diseases such e. g. Hepatitis B.


49

Name


FonFax

E-Mail Internet

Founded (year)

Name


FonFax

E-Mail Internet

Founded (year)

Name


Fon

E-Mail

Internet


With a unique combination of expertisein biology and chemistry, UCB is a globalbiopharma company focusing on severediseases in two therapeutic areas – CNSand Immunology. UCB also has a selective presence in primary care.

UCB is connecting science in new ways, notably chemistry and biology, so that they can leverage the potential of these

two disciplines, as well as illuminate the biological pathways involved in severe diseases.

The complexities of severe diseases are beyond the expertise and resources of a single organisation. That is why we have teamed up with partners – we play to our strengths and tap into the organisations with greater or complementary strengths.

Many companies claim to be patient driven, but for UCB it is a living reality. We do not think of people with severe diseases as “patients” but as individuals with lives beyond their disease.

Syntab Therapeutics is committed to the exploration and development of innovative drugs against severe diseases such as can-cer. Syntab’s synthetic antibodies exhibit all desirable properties of conventional antibodies while, at the same time, being significantly smaller chemically accessible molecules. The company strives for the

Transimmune AG is pioneering the re-search and development of extracorpor-eal immunotherapies for the treatment of human diseases. Transimmunization is the scientifically driven descendent of ex-tracorporeal photopheresis (ECP), a highly

early out-licensing of product candidates after completion of the preclinical devel-opment. Syntab’s platform technology enables the chemical synthesis of highly effective drugs against severe diseases such as cancer. The flexibility of the technology is based on the application of diverse highly specific binders against specific cell surface proteins.

Furthermore, the technology has the potential to vary the number and specific properties of binders and effectors that activate the immune system for each drug molecule.

successful immunological treatment used for many years, mainly in cutaneous T cell lymphoma and organ transplant. Transim-mune AG has built on principles learned from in-depth consideration of ECP’s introductory lessons and believes Tran-simmunization will significantly enhance current ECP as well as drive its application heavily into many new indications.

UCB GmbH


+49 2173 4848-48+49 2173 4848-41 [email protected]

1928 (Belgium)

Syntab Therapeutics GmbH

St.-Jobser-Straße 5652146 Würselen

+49 171 6558374

[email protected]<102010

Transimmune AG

Königsallee 9040212 Düsseldorf

+49 211 1684 9338+49 211 8693 [email protected]

2012

TRANSIMMUNE

50

BIO.NRW

Industrial Biotechnology

BIO.NRW industrial biotechnology

51

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet

Founded (year)

Autodisplay Biotech GmbH is a biotechnol-ogy company commercializing its propri-etary expression platform for the display of heterologous proteins or peptides on the surface of gram negative bacteria. This cell surface display technology provides

numerous benefits to biocatalysis, the func-tionalisation of solid surfaces and screening applications.

With its custom-tailored products and services, Autodisplay Biotech is an ideal partner for leading companies in the chemi-cal, pharmaceutical and biotechnology industries.

BSV BioScience GmbH was founded in Oct. 2007 in Baesweiler, near the historical city of Aachen. Since June 2010, the company manufactures and markets biological phar-maceutical active ingredients for different therapeutic areas.

One of our key strengths is based on the production of fertility hormones, being

supplied either as API or finished injecta-bles, in co-operation with an also GMP ap-proved German license manufacturer.

Our main products are:– Human Chorionic Gonadotrophin (HCG),– Human Menopausal Gonadotrophin (HMG),– Follicle Stimulating Hormone (FSH),– Urokinase (UK), Streptokinase and Ulinastatin (UTI).BSV BioScience GmbH is focused on differ-ent R&D activities, continuously pursuing improvements in the field of API´s and finished dosage forms.

Autodisplay Biotech GmbH

Merowinger Platz 1a40225 Düsseldorf

+49 211 20951378+49 211 [email protected]

102008

BSV Bioscience GmbH

Max-Planck-Strasse 12 52499 Baesweiler

+49 2401 8047-10+49 2401 [email protected]

182007

bitop AG

Stockumer Str. 2858453 Witten

+49 2302 914-400 +49 2302 914-4010 [email protected] 1993

bitop AG focuses on the development, manufacture and marketing of medical de-vices and high quality active ingredients for cosmetics. The technological base of bitop AG’s business are substances from the class of extremolytes, in particular the compound Ectoin®. Extremolytes are natural protective

molecules that are formed by microorgan-isms and plants. bitop AG produces such extremolytes in an industrial scale in its own facility in Witten according to its proprietary biotechnological production processes. bitop AG has developed Ectoin®-containing medical devices for the symptomatic treatment of cough and cold, allergies, dry mucosa, inflammatory skin diseases and airway diseases. The marketing and sale of these medical devices is performed by licensees from the pharmaceutical industry. Currently, bitop’s medical devices are avail-able in more than 40 countries worldwide.

BIO.NRWindustrial biotechnology

52

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


At Direvo, we focus on the emerging bio-mass conversion industry. We are develop-ing and marketing biology-based products and processes utilizing safe and sustain-able resources for a world still dominated by fossil raw materials. Our powerful scien-tific tools unleash the full value of biomass in current and novel industrial processes. Direvo is committed to deliver the best

The innovative biotechnology company Cysal GmbH was founded as a spin-out of the University of Münster, Germany.

Cysal focuses on the production of novel biomaterials in the area of biopolymers, peptides, amino acids, and dipeptides on an industrial scale at unprecedented low-cost, and also develops application fields

technologies supporting the needs of our customers and partners for sustainable and profitable processes which are urgently required by the developing BioEconomy.

evocatal GmbH is a biotechnology company specialized in the development and pro-duction of tailor-made biocatalysts and fine chemicals for the chemical and phar-maceutical industries. Its services include contract research and providing custom-ers with evocatal s unique biocatalysts to achieve more efficient and sustainable production processes. The broad base of

customers range from pharmaceutical companies, adhesive specialists, flavor, fragrance and cosmetic manufacturers to companies in the textile and building ma-terials industries. evocatal GmbH’s labo-ratories and technical center are based in Monheim am Rhein, which is located at the heart of the chemical triangle between the Ruhr area, Düsseldorf and Cologne.

for these biomaterials to serve humans and animals. Cysal’s business strategy aims at out-licensing its technology plat-form to interested companies and/or offering its raw materials for incorpora-tion into consumer products for various markets.

The main target markets are those for energy food additives and sport nutrition, cosmetics and skin care, dental hygiene, clinical nutrition, immunomodulation, impotence and infertility, as well as in the area of animal feed production, especially for aquaculture.

Direvo Industrial Biotechnology GmbH


+49 221 47448-0 +49 221 47448-111 [email protected]

302008

Cysal GmbH

Mendelstraße 1148149 Münster

+49 251 980-2490+49 251 [email protected]

52012

evocatal GmbH

Alfred-Nobel-Straße 1040789 Monheim am Rhein

+49 2173 40994-0 +49 2173 40994-40 [email protected]

352006


53

Name


FonFax

E-Mail Internet


Name


FonFax

Internet


Name


FonFax

E-Mail Internet

Founded (year)

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its inno-

vative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2013 more than 33,000 employees generated sales of around €12.9 billion and an operating profit (adjusted EBITDA) of about €2.0 billion.

Evonik innovates and serves the bioec-onomy markets. Products are i. a. Biolys®, DYNACOLL® Terra, DYNAPOL® Terra, RESOMER®, ThreAMINO®, TrypAMINO®, and VESTAMID® Terra.

Henkel operates worldwide with lead-ing brands and technologies in three business areas: Laundry & Home Care, Beauty Care and Adhesive Technolo-gies. Founded in 1876, Henkel holds globally leading market positions both in the consumer and industrial businesses with wellknown brands such as Persil, Schwarzkopf and Loctite.

Henkel employs about 47,000 people andreported sales of 16,428 million euros andadjusted operating profit of 2,588 million euros in fiscal 2014.

Henkel’s preferred shares are listed in the German stock index DAX.

Evonik Industries AG

Rellinghauser Str. 1-11 45128 Essen

+49 201 177 01+49 201 177 [email protected]

33,000 2007

Henkel AG & Co. KGaA

Henkelstr. 6740191 Düsseldorf

+49 211 7979630+49 211 7982245www.henkel.com

47,0001876

IMAX Discovery is a research driven company, creating new product innovation through the generation and development of novel and natural flavour compounds for the food and beverage industry.

Using our strong technology platforms and expertise around taste receptors and natural products IMAX Discovery generates propri-

etary product pipelines of natural product based novel taste modulators.

IMAX discovery is a 50:50 joint venture company between Axxam SpA in Milano, Italy, and IMD Natural Solutions GmbH in Dortmund, Germany.

IMAX Discovery GmbH


+49 231 9742-6440+49 231 9742-7401 [email protected]

2010


54

Name


FonFax

E-Mail Internet


multiBIND develops innovative decontami-nation, disinfection and hygiene solutions for e.g. molecular biology researchers and the healthcare industry. Core technology is a so-lution system to generate new disinfectants and decontamination agents for hospitals,

laboratories and other industries. Currently bioDECONT® and bioCLEAN are the only agents that in addition to the effective killing of microorganisms also accomplishes safe and complete degradation of their genetic material (DNA/RNA). Besides its highly ef-ficient antimicrobial action and decontami-nation properties, it is nontoxic for humans, non-corrosive and free of organic solvents or other hazardous chemicals. multiBIND pursues a partnering strategy by develop-ing new applications together with partners from suitable industry sectors. We are open for licensees in several applications.

Name


FonFax

E-Mail

Internet


IMD Natural Solutions (“INS”) aims to develop and commercialize groundbreak-ing ingredients - with a special focus on preserving and anti-microbial agents - de-rived from “all” natural sources. The main target markets are in the Food & Beverage as well as the Personal Care industries. Two product candidates are in advanced

development: AM-1 represents a new (patent pending) all natural antimicrobial preserving agent well suited to support product specifications for food, beverage and personal care applications. AX-1 is targeting oil preservation via its strong antioxidant profile. INS follows a dual busi-ness model; besides the development of preserving agents INS provides Natural Product Service as one-stop service part-ner for all needs associated with Natural Product research, development, produc-tion or supply.

IMD Natural Solutions GmbH

Otto-Hahn-Str. 1544227 Dortmund+49 231 9742-7400+49 231 9742-7401info@imd-natural-solutions.comwww.imd-natural-solutions.com102012

m2p-labs GmbH

Arnold-Sommerfeld-Ring 252499 Baesweiler

+49 2401 805330+49 2401 [email protected]

212005

m2p-labs is a worldwide leading supplier of microbioreactors for the Life-Science industry. The company’s product portfolio comprises the BioLector®, the RoboLec-tor® (automation) and the disposable FlowerPlate® (MTP) which provide an in-

telligent micro fermentation platform for screening and bioprocess development. This technology enables customers to increase their number and information of microbial experiments (aerobic, micro-aerophilic and strict anaerobic) and to con-duct experiments with greater efficiency, better quality and lower cost than in any other cultivation platform.

m2p-labs | The Microbioreactor Company

Name


FonFax

E-Mail Internet


multiBIND biotec GmbH

Gottfried-Hagen-Str. 60-6251105 Köln

+49 221 2780-211+49 221 [email protected]

32005


55

Name


FonFax

E-Mail Internet


Name


Fon E-Mail

Internet

Founded (year)

Senzyme GmbH develops and produces technical enzymes and other micro-biological products, all of which is well grounded in the company’s substantial experience in solid-state fermentation us-ing filamentous fungi. Currently, the focus

is on the development of intelligent mix-tures of hydrolases, to be used in a most efficient degradation of plant material, e.g. in the course of methane production from biomass.

Senzyme GmbH

Gierlichsstr. 653840 Troisdorf

+49 2241 9715-2000+49 2241 [email protected]

202000

SeSaM-Biotech GmbH

Forckenbeckstraße 5052074 Aachen

+49 241 [email protected]

2008

SeSaM-Biotech provides companies and institutes with novel enzymes for research or application in industrial or medical pro-cesses. Our platform technology Sequence Saturation Mutagenesis (SeSaM) is an in-novative and patented random mutagenesis

method for generating unbiased diversity of proteins to discover new enzyme function-alities or improve given enzyme properties. Our protein engineering services comprise of mutant gene library generation and enzyme evolution projects including high throughput screening for improved properties and sub-sequent characterization of enzyme kinetics to provide our customers with the most promising evolved enzyme variants tailored to their needs. To ensure top level research, we strongly cooperate with the Institute of Biotechnology of excellent RWTH Aachen University, held by Prof. Dr. Schwaneberg.

Taros has been serving the needs of phar-maceutical, chemical, agrochemical and biotech companies since 1999. We delivered more than 10.000 customer projects and combine more than 140 years industrial organic chemistry experience and over 60 years of active drug discovery experience with expertise across a broad range of

therapeutic areas (oncology, respiratory, CNS, cardiovascular, inflammation, pain, metabolism and infectious) and in all small molecule target classes. Taros operates state-of-the art lab facilities and employs a team of scientists, 65% of whom hold post-graduate degrees in Chemistry. We thought and developed TarosGate®, a unique soft-ware suite putting cost, time and chemistry information at a Project Leader’s finger tips - 24h/7 from anywhere in the world. TarosGate® is a major cornerstone of the 200 Mio. Euro European Lead Factory drug discovery platform.

Name


FonFax

E-Mail Internet


Taros Chemicals GmbH & Co. KG

Emil-Figge-Str. 76 A44227 Dortmund

+49 231 9742-7211+49 231 [email protected]

501999


56

Name


FonE-Mail

Internet


W42 GmbH is your partner for enzyme production and process development. We offer: High performance heterologous protein production in Pichia sp. Wide range of different strains and promoters – best choice for your project. Methanol dependent and Methanol independent high yield protein production. Complete processes are offered including: strain

development – fermentation – DSP – enzyme immobilisation. Since 2005 W42 GmbH has carried out many successful projects for industrial partners in Europe and P.R. China. Several improved strains are running on industrial scale for produc-tion of technical enzymes.

Furthermore W42 is working on rational strain improvement of microorganisms for the optimisation of industrial production of natural compunds (e.g. antibiotics).

W42 Industrial Biotechnology GmbH

Otto-Hahn-Straße 1544227 Dortmund

+49 231 9742 [email protected]

32005

57

BIO.NRW

bio.nrw.de company database

Innovative biotech companies in North Rhine-Westphalia. BIO.NRW offers free of charge a well-or-ganized and comprehensive database of life science and biotech companies resident in North Rhine-Westphalia. The database currently includes 400 company profiles, contact details and a summary of products, services and technologies and is updated frequently several times per year.

phone: +49 211 38 54 69-9200 • E-Mail: [email protected]

58

BIO.NRW

Agrobiotechnology

BIO.NRW agrobiotechnology

59

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet

Founded (year)

AgroProtect GmbH

Forckenbeckstraße 652074 Aachen

+49 241 6085 12010+49 241 6085 [email protected]

2010

Bayer CropScience AG


+49 21 73 383270+49 21 73 [email protected]

23,1001863

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer CropScience, the subgroup of Bayer AG responsible for the agricultural business, has annual sales of EUR 9,494 million (2014) and is one of the world’s leading innovative crop science companies in the areas of seeds, crop protection and non-agricultural pest control. The company

German Seed Alliance GmbH is an alliance of four leading German plant breeding companies in international agriculture: Deutsche Saatveredelung, Norddeutsche Pflanzenzucht, Nordsaat Saatzucht and SaKa. The company and its shareholders are internationally experienced enterprises in the field of plant research and development, breeding, seed production and distribution.

It is estimated that plant pathogens are re-sponsible of world-wide losses in the range of billions of Euros per year. Therefore, there is a strong need to provide effective, broad range and environmentally friendly approaches to ensure protection of plants

offers an outstanding range of products including high value seeds, innovative crop protection solutions based on chemical and biological modes of action as well as an extensive service backup for modern, sustainable agriculture. In the area of non-agricultural applications, Bayer Crop-Science has a broad portfolio of products and services to control pests from home and garden to forestry applications. The company has a global workforce of 23,100 and is represented in more than 120 countries.

The main focus is on oilseed rape, potatoes, corn, sunflower, grasses, peas and cere-als (especially wheat, barley, rye, oat and triticale). German Seed Alliance coordinates all research programs of the group and is partner of the national and international scientific community in plant research and biotechnology. New varieties are developed and high quality seeds are produced for dif-ferent climate regions. In sales the first focus is on Russian Federation, with innovative solutions and wide range of seed products combined with professional service and individual consultancy.

from pathogens. We developed a patented platform based on antibody fusions which ensures plant protection from fungal and bacterial infections. This alternative ap-proach for controlling plant pathogens and parasites aims at minimising the costs for cultivation of crops thereby reducing the toxic effects of pesticides and toxins for human beings.

AgroProtect GmbH licences its propri-etary technology and offers the genera-tion of pathogen resistant plants as well as access to novel resistant cultivars of several crops.

German Seed Alliance GmbH

Erdmund-Rumpler-Straße 651149 Köln

+49 2203 9888-20+49 2203 [email protected]

452008

BIO.NRWagrobiotechnology

60

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet

Founded (year)

Phytowelt is operating in the field of indus-trial plant biotechnology. It is a leading pro-vider for the identification and expression of genes encoding plant enzymes with new activities for industrial fermentation pro-cesses with a main activity on fatty acids, terpenoids and plant P450 enzymes. Ad-ditionally Phytowelt offers solutions in plant

breeding to improve plants by protoplast fu-sion. Phytowelt’s improvement of biomass production by this accelerated breeding process is the basis for the biorefinery concept to be realized in Nettetal in the coming years. The USP of a poplar breed-ing collection combined with the unique fermentation process for terpenes in E.coli, especially carotinoids like astaxanthin and beta-carotene is one of the success factors for Phytowelt. Alpha-Ionone will be one of the first products fermentatively produced.

The company MykoMax was created in October 1999 in the legal form of a limited company (GmbH). The enterprise article of the society is the study, development and production of biotechnology products on the basis of fungi. The company offers al-

ready within the mycological product range several self-developed mycorrhiza-inoculi.

On short and medium-term the company MykoMax GmbH would development new drugs from medicinal effective mushrooms for the pharmaceutical use. Thereby the company uses a self-developed method for the extraction of the active ingredients in the mushrooms.

Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality.

Monsanto remains focused on enabling both small-holder and large-scale farm-ers to produce more from their land while

conserving more of our world’s natural resources such as water and energy.

Monsanto Agrar Deutschland GmbH

Vogelsanger Weg 9140470 Düsseldorf

+49 211 3675-0+49 211 [email protected]

2000

Phytowelt GreenTechnologies GmbH

Kölsumer Weg 3341334 Nettetal

+49 2162 77859+49 2162 89215 [email protected]

30 1998

MykoMax GmbH

Flieth 3942327 Wuppertal

+49 202 3171-320+49 202 [email protected]

31999

BIO.NRW agrobiotechnology

61

Name


FonFax

E-Mail Internet


Name


FonE-Mail

Internet


Name


FonFax

E-Mail

Internet


Saaten-Union Biotec GmbH

Hovedisser Str. 9233818 Leopoldshöhe

+49 5208 9597-10+49 5208 9597-195 [email protected] 1984

W. von Borries-Eckendorf GmbH & Co. KGPflanzenzuchtbetrieb

Hovedisser Str. 92 33818 Leopoldshöhe+49 5208 9125-30+49 5208 9125-49 [email protected]

401849

W. von Borries-Eckendorf is a medium-sized family-owned company, founded in 1849 by Wilhelm von Borries (1805-1890), a prominent farmer and talented plant breeder. Starting with the “Eckendorfer”

fodder beet, WvB is nowadays well known for strong breeding programs in oilseed rape, barley and high yielding wheat varieties.

The company based in Lippe is founding member of the Rapool Ring GmbH and the Saaten-Union Biotec GmbH.

Along with other breeding companies, Eckendorf is significantly involved in one of the largest distributors in the German sector of seed. The Saaten-Union GmbH.

ECK

EN

D

OR F E R

SO

RT

E

N

Saaten-Union Biotec offers services and contract research in the field of plant breeding (wheat, rapeseed, barley, triti-cale, oat, hybrid rye, durum wheat, fodder and amenity grasses). The development

BIOTEC

of new varieties of cereals, rapeseed and other crops is strongly build upon innovation. Application of tissue culture technologies (doubled haploids, embryo rescue) and molecular marker applica-tions are routinely used in a wide range of crops and for a significant number of breeding traits.

Syngenta Seeds GmbH

Zum Knipkenbach 20 32107 Bad Salzuflen

+49-5222 [email protected]

1502000

Syngenta is one of the world’s leading companies in agribusiness with more than 26,000 employees in over 90 countries. We are dedicated to our purpose: Bringing plant potential to life.

Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve health and

quality of life. At the core of our business is innovation, particularly in research and development, combining chemical and biological expertise.

We harness our knowledge of agricul-ture and our understanding of growers to develop integrated offers which will drive land productivity in a sustainable way.

62

BIO.NRW

Bioinformatics

BIO.NRW bioinformatics

63

Ridom GmbH

Mendelstr. 1148149 Münster

+49 251 490931-50+49 251 [email protected] www.ridom.de

42003

The Ridom GmbH (Münster, Germany) was founded January 2003. The company devel-ops software for DNA re-sequencing analysis for physicians and epidemiologists on routine basis. The company has in the meantime by its software products a well-recognized name in the field of sequence based microbial typing; e.g., every European National Health

System Authority (e.g., RKI, RIVM, HPA, Se-rum Statens) has bought in the last 10 years and is using since then at least one software product from Ridom.

Ridom has pioneered typing efforts with a software tool for Staphylococcus aureus. The company has developed and maintains the worldwide largest sequence-based microbial typing database (Ridom SpaServer). The SPA typing software Ridom StaphType is currently used by approximately 400 users in 36 dif-ferent countries worldwide.

The new Ridom SeqSphere+ software provides a bacterial typing solution for any bacteria, any study type, any lab.

Name


FonFax

E-Mail Internet


64

BIO.NRW

North Rhine-Westphalia is situated at Eu-rope’s geographic and economic center. It is the largest of Germany’s 16 federal states, and the number one exporter. If classified as an independent exporting nation, NRW would rank 19th in the world, on a par with the Netherlands.

North Rhine-Westphalia’s state gov-ernment has established a number of technology clusters to systematically improve NRW’s strengths and talents in established industries and up-and-coming fields like biotechnology.

North Rhine-Westphalia’s biotechnology cluster BIO.NRW is a central catalyst for the sustainable development of the state’s biotech sector. It activates cooperation between business, research, investors and policy-makers. The cluster also promotes the strengths and achievements of biotech-nology in the state.

To support young as well as already estab-lished biotech companies, BIO.NRW offers the following core competencies:– Individual matchmaking for collabora-

tions and partners– Overview on all up-to-date R&D activi-

ties in industry and academia– Profound knowledge on financing pos-

sibilities– International promotion and marketing

for NRW as biotech location– Direct contacts to decision makers

Our services include

Technology TransferTech transfer support is a key contribution from BIO.NRW. We organize events, work-ing platforms and meetings to promote the

BIO.NRW Cluster Biotechnology North Rhine-Westphalia

biotech developments in NRW please visit www.bio.nrw.de.

Further drivers in the field are dynamic local biotechnology initiatives and networks:

Bioanalytik-Münster www.bioanalytik-muenster.de

BioColognewww.biocologne.de

bio.dortmundwww.wirtschaftsfoerderung-dortmund.de

BioIndustrywww.bioindustry.de

BioRiverwww.bioriver.de

Bio-Tech-Region OWLwww.bio-owl.de

LifeScienceNet Düsseldorfwww.lifescience-dus.de

MedLife (Aachen)www.medlife-ev.de

Cluster Industrial Biotechnologywww.CLIB2021.com

dialogue between all stakeholders in the field of biotechnology and to encourage cooperation.

Biotech Business & SciencesBIO.NRW compiles comprehensive and current online databases of the academic institutions and companies active in the life sciences in NRW. Free to access and easy-to-use, these resources are valuable tools for identifying prospective business part-ners. More information on www.bio.nrw.de

Fairs, Exhibitions and ConferencesCompanies and academic institutions can generate awareness of their activities lo-cally, nationally and internationally by being a part of the BIO.NRW common stands on fairs, exhibitions and conferences. BIO.NRW also organizes a series of workshops and symposia, called BIO.NRW.academy.

Support of Young ProfessionalsBIO.NRW takes a special interest in sup-porting young professionals in biotechnol-ogy. For example, we organize conventions where graduates meet representatives from industry and academic science. The ‘Business Angel Network – BIO.NRW’ helps financing and funding biotech start-ups. In addition, a forum that brings together investment institutions, private investors and business angels and developers pro-vides information about the current NRW biotech scene. These meetings are a valu-able opportunity for start-up companies to receive coaching and financing.

To learn more about the Cluster BIO.NRW and to stay informed about the latest

65

BIO.NRW

München

Dresden

Potsdam

Hannover

j

Düsseldorf

Schwerin

Magdeburg

Kiel

Erfurt

Stuttgart

Saarbrücken

Frankfurt

Mainz

Berlin

Bremen

Hamburg

Poland

AustriaSwitzerland

France

Netherland

Czech Republic

Denmark

Luxembourg

Belgium

66

Glossary

Organisation for Economic Co-operation and Development (OECD)

The OECD is a unique forum where the gov-ernments of 30 democracies work together to address the economic, social and environ-mental challenges of globalisation.

The OECD Biotechnology Statistics, which brings together the latest available economic and activity data on biotechnology and in-novation, is collected by OECD member and non-member countries.

The report builds on the extensive work of the OECD and national experts to im-prove the comparability of biotechnology statistics.

www.oecd.org

OECD Definitions

Biotechnology company

… is defined as a application of science and technology to living organisms, as well as parts, products and models thereof, to alter living or non-living materials for the produc-tion of knowledge, goods and services.

Dedicated biotechnology companies

… are defined as biotechnology active firms whose predominant activities involve the application of biotechnology techniques to produce goods or services and/or the per-formance of biotechnology R&D.

Other biotechnologically active companies

… firms that apply biotechnology techniques for the purpose of implementing new or sig-nificantly improved products or processes.

This definition excludes end users that innovate simply by using biotechnol-ogy products as intermediate inputs (for instance, detergent manufacturers that change a formulation to include enzymes produced by other firms via biotechnology techniques).

Business Areas of Activity

– Health/Medicine (including animal health)

Development of therapeutics and/or diag-nostics for the field of human medicine, drug delivery, human tissue replacement.

– Agri/Agrobiotechnology Biotech focussed on genetically modified plants, animals or microorganisms, as well as non-genetically modified plants grown using biotechnological procedures for use in agriculture or forestry.

– Industrial biotechnologyBiotechnological products and processes for the handling of waste or sewage, for chemical synthesis, for the extraction of raw materials and energy, etc.

– Non-specific applicationEquipment or reagents based on biotechno-logical principles for research or provision of services in this field (“ancillary industry”).

Source: biotechnologie.de

BIO.NRW

Contact BIO.NRW

Dr. Christoph BlockHead of office BIO.NRWMerowingerplatz 140225 Düsseldorf, Germany

Fon +49 211 385469-9202Fax +49 211 385469-9220

[email protected]

Sources, Literature, Links

[1] www.nrwinvest.com/en/nrw-at-a-glance/nrw-economic-comparison

[2] www.nrwinvest.com/en/industries-nrw/chemical-industry

[3] Analysis by BIO.NRW[4] OECD Biotechnology Statistics 2009, B. van

Beuzekom and A. Arundel[5] NRW PCT Biotech Patent Analysis by BIO.NRW[6] The German Biotechnology Sector 2015;

www.biotechnologie.de[7] DIW Wochenbericht 32, 2011: Forschen

deutsche Großunternehmen zu wenig?[8] www.biotechgate.com; Venture Valuation,

Zurich, CH[9] 10. BCG Biotech-Report “Medizinische

Biotechnologie in Deutschland 2005 – 2015 - 2025”; www.vfa-bio.de

67

BIO.NRW

bio.nrw.de

BIO-Europe 2016November 7th-9th, Cologne

68

BIO.NRW

BIO.NRWMerowingerplatz 1 40225 Duesseldorf GermanyFon + 49 (0) 2 11 385 469 - 9200Fax + 49 (0) 2 11 385 469 - [email protected]

Ministry of Innovation, Science, Research and Technology of the State of North Rhine-Westphalia 40221 Duesseldorf www.innovation.nrw.de

www.exzellenz.nrw.de ‘Excellence NRW’ stands for the cluster strat-egy in North Rhine-Westphalia, an innovative location for business. The state government there wants to improve on its strengths, and systematically strive for excellence in NRW. The goal of the cluster policy is to create an environment that is friendly to innovation, strengthens the competitive edge of the businesses there, and stimulates growth and employment. To find out more about NRW’s cluster strategy and the 16 clusters in the state, just visit: www.exzellenz.nrw.de

BIO.NRWMerowingerplatz 1 40225 Düsseldorf, GermanyFon +49 211 385469-9200Fax +49 211 [email protected]

Ministry of Innovation, Science and Research of the German State of North Rhine-Westphalia 40221 Düsseldorf www.innovation.nrw.de

ww

w.b

io.n

rw.d

e

Company

Directory

Spot on Biotechnology Business 2015/2016

Online

Company

Database

www.bio.nrw.de

Online

Company

Database

www.bio.nrw.de

spot on biotechnology business 2015/16

Documents